GenCore version 5.1.3

OM nucleic - nucleic search, using sw model

Run on: March 30, 2003, 06:27:29 ; Search time 593 Seconds
(without alignments)
9748.532 Million cell updates/sec

Title: US-09-988-971-1
Perfect score: 2567
Sequence: 1 cccacgcgtccggtcggagc.....aaaaaaaaaaaaaaaaaaa 2567

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 2185239 seqs, 1125999159 residues

Word size : 0

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 100 summaries

Database : N_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	1132	44.1	1183	24	ABK61465	Human cDNA encodin
	2	786	30.6	786	24	AAL44089	Human modulator of
	3	733	28.6	837	21	AAC77202	Human ORFX ORF2757
	4	542	21.1	705	22	AAK56376	Human immune/haema
	5	534	20.8	737	24	AAL44090	Mouse MARS short i
	6	452	17.6	2049	23	AAS74750	DNA encoding novel
	7	405	15.8	603	23	AAS74748	DNA encoding novel
c	8	244	9.5	445	23	AAS74747	DNA encoding novel
	9	219	8.5	273	22	AAK67918	Human immune/haema
	10	192	7.5	211	23	AAS70181	DNA encoding novel
	11	134	5.2	432	22	ABA44128	Human breast cell
	12	134	5.2	432	22	ABA54580	Human foetal liver
	13	134	5.2	432	22	ABA24363	Probe #2829 for ge
	14	134	5.2	432	22	AAK02872	Human brain expres
	15	134	5.2	432	22	AAK28314	Human bone marrow
	16	134	5.2	432	22	AAI12879	Probe #2812 for ge
	17	134	5.2	432	22	AAI34236	Probe #2922 used t
	18	134	5.2	432	22	AAI02797	Probe #2788 used t
	19	134	5.2	432	24	ABS02823	Human genome-deriv
	20	134	5.2	448	22	AAI14520	Probe #4453 for ge
	21	134	5.2	448	24	ABS04499	Human genome-deriv
c	22	109	4.2	122	21	AAC12486	Human secreted pro
	23	96	3.7	96	22	ABA49284	Human breast cell
	24	96	3.7	96	22	ABA67198	Human foetal liver
	25	96	3.7	96	22	ABA34292	Probe #12758 for g
	26	96	3.7	96	22	AAK15640	Human brain expres
	27	96	3.7	96	22	AAK41374	Human bone marrow
	28	96	3.7	96	22	AAI22119	Probe #12052 for g
	29	96	3.7	96	22	AAI47414	Probe #16100 used
	30	96	3.7	96	22	AAI07818	Probe #7809 used t
	31	96	3.7	96	24	ABS15380	Human genome-deriv
c	32	71	2.8	361	22	AAK89725	Human digestive sy
c	33	69	2.7	373	22	AAL07037	Human reproductive
c	34	69	2.7	373	22	AAI62715	Human breast or ov
	35	65	2.5	579	22	AAH09392	Human cDNA clone (
c	36	65	2.5	1729	22	AAH17124	Human cDNA sequenc
	37	65	2.5	12541	22	AAL35819	Human musculoskele
	38	65	2.5	13467	22	AAL05944	Human reproductive
	39	65	2.5	13467	22	AAS27670	DNA encoding novel
	40	65	2.5	13467	22	AAS27838	DNA encoding novel
	41	65	2.5	13467	22	AAK85539	Human immune/haema
	42	65	2.5	13467	23	ABL98508	Human testicular a
c	43	64	2.5	749	20	AAZ24851	Human secreted pro
	44	64	2.5	23989	22	AAK72555	Human immune/haema
	45	64	2.5	112460	24	ABK83567	Human cDNA differe
	46	63	2.5	23394	22	AAK77173	Human immune/haema
	47	61	2.4	405	22	AAL03793	Human reproductive
	48	61	2.4	405	22	AAI62607	Human breast or ov
	49	61	2.4	405	23	ABK72132	Human ovarian anti
	50	61	2.4	405	24	ABK91724	Novel ovarian rela
	51	61	2.4	418	22	AAL00601	Human reproductive
	52	61	2.4	418	22	AAI62488	Human breast or ov
	53	61	2.4	418	23	ABK72088	Human cDNA encodin
	54	61	2.4	418	24	ABK91680	cDNA encoding nove
	55	61	2.4	458	23	ABV50873	Human prostate exp
c	56	61	2.4	2007	22	AAH15514	Human cDNA sequenc
c	57	61	2.4	6186	22	AAS28641	Genomic sequence #
c	58	61	2.4	6191	22	AAS28642	Genomic sequence #
c	59	61	2.4	6191	22	AAS28643	Genomic sequence #
	60	61	2.4	6191	23	ABK42222	Genomic sequence #
	61	61	2.4	6194	23	ABK42223	Genomic sequence #
	62	61	2.4	25525	22	ABA19375	Human nervous syst
	63	61	2.4	26713	22	AAK71186	Human immune/haema
	64	61	2.4	31994	22	AAS30619	DNA encoding novel
	65	61	2.4	31994	22	AAS28165	Genomic sequence #
	66	61	2.4	81001	22	AAF30035	Human apolipoprote
c	67	61	2.4	154465	24	AAD28763	Human AKAP allelic
c	68	61	2.4	158245	24	AAD28762	Human AKAP allelic
c	69	61	2.4	161425	22	AAH02340	Human AKAP10 gene
c	70	61	2.4	162025	22	AAH02339	Human AKAP10 gene
c	71	61	2.4	162025	24	AAD28758	Human AKAP allelic
c	72	61	2.4	162025	24	AAD28759	Human AKAP allelic
	73	60	2.3	60	24	ABN35717	Human spliced tran
	74	60	2.3	8174	12	AAQ13332	GDP-Fuc:beta-D-gal
	75	60	2.3	8174	15	AAQ56908	DNA encoding a gly
	76	60	2.3	8174	18	AAT61677	Human alpha(1,2)-f
	77	59	2.3	347	21	AAC29077	Human secreted pro
	78	59	2.3	388	22	AAI92145	Human polynucleoti
	79	59	2.3	397	22	AAI91256	Human polynucleoti
c	80	59	2.3	446	23	ABV57344	Human prostate exp
c	81	59	2.3	975	22	AAK73114	Human immune/haema
c	82	59	2.3	975	22	AAK87585	Human immune/haema

c	83	59	2.3	979	22	AAK73094	Human immune/haema
c	84	59	2.3	979	22	AAK87563	Human immune/haema
c	85	59	2.3	1181	24	ABN99401	Human secreted pro
c	86	59	2.3	1376	21	AAC99845	Human secreted pro
c	87	59	2.3	2339	22	AAH16964	Human cDNA sequenc
c	88	59	2.3	10119	22	AAK87559	Human immune/haema
c	89	59	2.3	10800	22	AAK83329	Human immune/haema
	90	59	2.3	11172	22	AAS29967	Human lung antigen
c	91	59	2.3	14983	22	AAK73075	Human immune/haema
c	92	59	2.3	14983	22	AAK87542	Human immune/haema
	93	59	2.3	16759	24	ABL36297	Human lysosomal ac
	94	59	2.3	24218	22	AAK71828	Human immune/haema
c	95	59	2.3	24218	22	AAK73088	Human immune/haema
c	96	59	2.3	24218	22	AAK87556	Human immune/haema
	97	59	2.3	24218	22	AAI62935	Human genomic DNA
c	98	59	2.3	30803	22	AAK68410	Human immune/haema
	99	59	2.3	31741	22	ABA21231	Human nervous syst
	100	59	2.3	32152	22	ABA08132	Human ovarian and

ALIGNMENTS

RESULT 1
ABK61465
ID ABK61465 standard; cDNA; 1183 BP.
XX
AC ABK61465;
XX
DT 18-JUN-2002 (first entry)
XX
DE Human cDNA encoding protein NOV13.
XX
KW Human; gene; ss; NOVX; gene therapy; cardiomyopathy; atherosclerosis;
KW cell signal processing disorder; metabolic pathway modulation disorder;
KW diabetes; cancer; adenocarcinoma; lymphoma; prostate cancer;
KW uterus cancer; immune response; graft-versus-host disease;
KW acquired immunodeficiency syndrome; AIDS; asthma; Crohn's disease;
KW hypertension; congenital heart defects; multiple sclerosis; inflammation;
KW Albright hereditary osteodystrophy.
XX
OS Homo sapiens.
XX
PN WO200216599-A2.
XX
PD 28-FEB-2002.
XX
PF 27-AUG-2001; 2001WO-US26510.
XX
PR 25-AUG-2000; 2000US-228191P.
PR 08-FEB-2001; 2001US-267300P.
PR 20-FEB-2001; 2001US-269961P.
PR 20-MAR-2001; 2001US-277337P.
XX
PA (CURA-) CURAGEN CORP.
PA (CORT-) COR THERAPEUTICS INC.
XX
PI Burgess CE, Conley PB, Grosse WM, Hart M, Kekuda R, Shimkets RA;
PI Spytek KA, Szekeres ES, Tomlinson JE, Topper JN, Yang R;
XX
DR WPI; 2002-280937/32.
DR P-PSDB; AAU91308.
XX
PT New polypeptides for treating or preventing a disorder associated with
PT them, in humans, e.g. cardiomyopathy, atherosclerosis or cancers -
XX
PS Claim 1; Page 98; 263pp; English.
XX
CC The invention relates to an isolated polypeptide (NOVX) a mature
CC form of NOVX, a NOVX variant (differing by no more than 15%), the
CC nucleotide encoding NOVX (or its complement, fragment or variant).
CC NOVX is NOV1-14, 15a, 15b, 16a, and 16b. The NOVX polypeptide, nucleic
CC acid encoding it and antibody against it, are useful for treating or
CC preventing (e.g. by gene therapy) a NOVX-associated disorder in humans,
CC e.g. cardiomyopathy, atherosclerosis, a disorder related to cell signal
CC processing and metabolic pathway modulation, diabetes or cancers. The
CC NOVX polypeptide and nucleic acids are also useful for determining the
CC presence of predisposition to the diseases. The NOVX nucleic acid and
CC polypeptide are especially useful in therapeutic or prophylactic
CC applications for disorders associated with aberrant NOVX expression or
CC activity, e.g. cancers (e.g. adenocarcinoma, lymphoma, prostate cancer or
CC uterus cancer), immune response, graft-versus-host disease, acquired
CC immunodeficiency syndrome (AIDS), asthma, Crohn's disease, hypertension,
CC congenital heart defects, multiple sclerosis, inflammation or Albright
CC hereditary osteodystrophy and many other diseases listed in the
CC specification. The DNA encoding the protein is useful in gene therapy
CC for treating the conditions. This is also useful in detection assays,
CC chromosome mapping, tissue typing, diagnostic or prognostic assays, or
CC for developing a powerful assay system for functional analysis of
CC various human disorders, as well as in diagnostic applications. The
CC present sequence encodes a NOVX protein.
XX
SQ Sequence 1183 BP; 251 A; 359 C; 333 G; 240 T; 0 other;

Query Match 44.1%; Score 1132; DB 24; Length 1183;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1182; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy     18 AGCTAGAGCTCCAAGGACCCCACGCCTGTGTCTCTGTGACAGAGCTCAAAGGGCCCTGGG 77
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 AGCTAGAGCTCCAAGGACCCCACGCCTGTGTCTCTGTGACAGAGCTCAAAGGGCCCTGGG 60

Qy     78 CCTTCCCTCCCTGGCTCGGCTGTGCTTGGGAGGGTTCCCCAGTCCAGAATCCCTAAGGAG 137
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 CCTTCCCTCCCTGGCTCGGCTGTGCTTGGGAGGGTTCCCCAGTCCAGAATCCCTAAGGAG 120

Qy    138 CATGGGGCAGCTGATCCATCCCTGGTGTACAAACTGCTGACTGCAGACAGATGCTGAGCT 197
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 CATGGGGCAGCTGATCCATCCCTGGTGTACAAACTGCTGACTGCAGACAGATGCTGAGCT 180

Qy    198 ACCCAAACCAACACCTAGCCTCTCCCTGAAGATCCTCCCAGGCTGAGAGAGTTCTGGGTG 257
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 ACCCAAACCAACACCTAGCCTCTCCCTGAAGATCCTCCCAGGCTGAGAGAGTTCTGGGTG 240

Qy    258 TCCTAGGACCAAGGACACTGGCAGACTTCCAGAAGGGCCCCCAAAGCCCTAACCTGTCCA 317
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 TCCTAGGACCAAGGACACTGGCAGACTTCCAGAAGGGCCCCCAAAGCCCTAACCTGTCCA 300

Qy    318 GCCAGAGCATGCGTCTCAGCAGAGCTGTCTTCCCAAGCCTTTGATGACAAACCAATTTCC 377
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 GCCAGAGCATGCGTCTCAGCAGAGCTGTCTTCCCAAGCCTTTGATGACAAACCAATTTCC 360

Qy    378 CTCGATGATGTGCTTCTGAGTGCTCTGCTGAGGAACAATGGGAAGTCTGCCCAGCAGAAG 437
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 CTCGATGATGTGCTTCTGAGTGCTCTGCTGAGGAACAATGGGAAGTCTGCCCAGCAGAAG 420

Qy    438 AAAATCTCTGCCAAGCCCAAGCTTGAGTTCCTCTGTCCAAGGCCAGGGACCTGTGACCAT 497
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 AAAATCTCTGCCAAGCCCAAGCTTGAGTTCCTCTGTCCAAGGCCAGGGACCTGTGACCAT 480

Qy    498 GGAAGCAGAGAGAAGCAAGGCCACAGCCGTGGCCCTGGGCAGTTTCCCGGCAGGTGGCCC 557
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 GGAAGCAGAGAGAAGCAAGGCCACAGCCGTGGCCCTGGGCAGTTTCCCGGCAGGTGGCCC 540

Qy    558 GGCCGAGCTGTCGCTGAGACTCGGGGAGCCATTGACCATCGTCTCTGAGGATGGAGACTG 617
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    541 GGCCGAGCTGTCGCTGAGACTCGGGGAGCCATTGACCATCGTCTCTGAGGATGGAGACTG 600

Qy    618 GTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTATAACATCCCCAGCGTCCACGTGGC 677
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    601 GTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTATAACATCCCCAGCGTCCACGTGGG 660

Qy    678 CAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGCAGGGAGAAAGCAGAGGAACTGCT 737
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    661 CAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGCAGGGAGAAAGCAGAGGAACTGCT 720
```

```
Qy     738 GTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATCCGGGAGAGCCAGACCAGGAGAGG 797
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 GTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATCCGGGAGAGCCAGACCAGGAGAGG 780

Qy     798 CTCTTACTCTCTGTCAGTCCGCCTCAGCCGCCCTGCATCCTGGGACCGGATCAGACACTA 857
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 CTCTTACTCTCTGTCAGTCCGCCTCAGCCGCCCTGCATCCTGGGACCGGATCAGACACTA 840

Qy     858 CAGGATCCACTGCCTTGACAATGGCTGGCTGTACATCTCACCGCGCCTCACCTTCCCCTC 917
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     841 CAGGATCCACTGCCTTGACAATGGCTGGCTGTACATCTCACCGCGCCTCACCTTCCCCTC 900

Qy     918 ACTCCAGGCCCTGGTGGACCATTACTCTGAGCTGGCGGATGACATCTGCTGCCTACTCAA 977
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 ACTCCAGGCCCTGGTGGACCATTACTCTGAGCTGGCGGATGACATCTGCTGCCTACTCAA 960

Qy     978 GGAGCCCTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGT 1037
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     961 GGAGCCCTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGT 1020

Qy    1038 GACTGTGCAGAGGACACCACTCAACTGGAAAGAGCTGGACAGCTCCCTCCTGTTTTCTGA 1097
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1021 GACTGTGCAGAGGACACCACTCAACTGGAAAGAGCTGGACAGCTCCCTCCTGTTTTCTGA 1080

Qy    1098 AGCTGCCACAGGGGAGGAGTCTCTTCTCAGTGAGGGTCTCCGGGAGTCCCTCAGCTTCTA 1157
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1081 AGCTGCCACAGGGGAGGAGTCTCTTCTCAGTGAGGGTCTCCGGGAGTCCCTCAGCTTCTA 1140

Qy    1158 CATCAGCCTGAATGACGAGGCTGTCTCTTTGGATGATGCCTAG 1200
           |||||||||||||||||||||||||||||||||||||||||||
Db    1141 CATCAGCCTGAATGACGAGGCTGTCTCTTTGGATGATGCCTAG 1183
```

RESULT 2
AAL44089
ID AAL44089 standard; cDNA; 786 BP.
XX
AC AAL44089;
XX
DT 03-OCT-2002 (first entry)
XX
DE Human modulator of antigen receptor signalling protein coding sequence.
XX
KW Human; gene; ss; gene therapy; modulator of antigen receptor signalling;
KW MARS; tumour suppressor gene; Scr-like adaptor protein; SLAP;
KW myeloid malignancy; acute myelogenous leukaemia; autoimmune disorder;
KW immunosuppression; myeloproliferative disorder; breast cancer.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..786
FT /*tag= a
FT /product= "Human MARS protein"
XX
PN WO200242452-A2.
XX
PD 30-MAY-2002.
XX
PF 26-NOV-2001; 2001WO-CA01662.
XX
PR 27-NOV-2000; 2000CA-2324663.
XX
PA (HOSP-) HOSPITAL FOR SICK CHILDREN.
XX
PI Mcglade JC, Loreto MP;
XX
DR WPI; 2002-566564/60.
DR P-PSDB; AAO15457.
XX
PT New isolated modulator of antigen receptor signaling protein or its
PT fragment, useful for treating malignant disorders such as myeloid
PT malignancies, autoimmune disorders and myeloproliferative disorders -
XX
PS Claim 12; Page 75; 110pp; English.
XX
CC The invention comprises the amino acid and coding sequences of modulator
CC of antigen receptor signalling (MARS) proteins. The MARS protein is a
CC putative tumour suppressor gene and exhibits structural and sequence
CC similarity to the Scr-like adaptor protein (SLAP). The MARS DNA and
CC protein sequences of the invention are useful for the treatment of
CC myeloid malignancies (e.g. acute myelogenous leukaemia) autoimmune
CC disorders, immunosuppression, myeloproliferative disorders and
CC malignancies related to the de-regulation of tyrosine kinases (e.g.
CC breast cancer). The present cDNA sequence encodes a human MARS protein.
XX
SQ Sequence 786 BP; 162 A; 234 C; 231 G; 159 T; 0 other;

Query Match 30.6%; Score 786; DB 24; Length 786;
Best Local Similarity 100.0%; Pred. No. 2.4e-285;
Matches 786; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy     415 ATGGGAAGTCTGCCCAGCAGAAGAAAATCTCTGCCAAGCCCAAGCTTGAGTTCCTCTGTC 474
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 ATGGGAAGTCTGCCCAGCAGAAGAAAATCTCTGCCAAGCCCAAGCTTGAGTTCCTCTGTC 60

Qy     475 CAAGGCCAGGGACCTGTGACCATGGAAGCAGAGAGAAGCAAGGCCACAGCCGTGGCCCTG 534
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CAAGGCCAGGGACCTGTGACCATGGAAGCAGAGAGAAGCAAGGCCACAGCCGTGGCCCTG 120

Qy     535 GGCAGTTTCCCGGCAGGTGGCCCGGCCGAGCTGTCGCTGAGACTCGGGGAGCCATTGACC 594
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 GGCAGTTTCCCGGCAGGTGGCCCGGCCGAGCTGTCGCTGAGACTCGGGGAGCCATTGACC 180

Qy     595 ATCGTCTCTGAGGATGGAGACTGGTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTAT 654
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 ATCGTCTCTGAGGATGGAGACTGGTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTAT 240

Qy     655 AACATCCCCAGCGTCCACGTGGCCAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGC 714
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 AACATCCCCAGCGTCCACGTGGCCAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGC 300

Qy     715 AGGGAGAAAGCAGAGGAACTGCTGTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATC 774
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 AGGGAGAAAGCAGAGGAACTGCTGTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATC 360

Qy     775 CGGGAGAGCCAGACCAGGAGAGGCTCTTACTCTCTGTCAGTCCGCCTCAGCCGCCCTGCA 834
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 CGGGAGAGCCAGACCAGGAGAGGCTCTTACTCTCTGTCAGTCCGCCTCAGCCGCCCTGCA 420

Qy     835 TCCTGGGACCGGATCAGACACTACAGGATCCACTGCCTTGACAATGGCTGGCTGTACATC 894
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 TCCTGGGACCGGATCAGACACTACAGGATCCACTGCCTTGACAATGGCTGGCTGTACATC 480

Qy     895 TCACCGCGCCTCACCTTCCCCTCACTCCAGGCCCTGGTGGACCATTACTCTGAGCTGGCG 954
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 TCACCGCGCCTCACCTTCCCCTCACTCCAGGCCCTGGTGGACCATTACTCTGAGCTGGCG 540

Qy     955 GATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGCCCGCTCCCT 1014
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 GATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGCCCGCTCCCT 600

Qy    1015 GGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGGAAAGAGCTG 1074
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 GGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGGAAAGAGCTG 660

Qy    1075 GACAGCTCCCTCCTGTTTTCTGAAGCTGCCACAGGGGAGGAGTCTCTTCTCAGTGAGGGT 1134
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 GACAGCTCCCTCCTGTTTTCTGAAGCTGCCACAGGGGAGGAGTCTCTTCTCAGTGAGGGT 720

Qy    1135 CTCCGGGAGTCCCTCAGCTTCTACATCAGCCTGAATGACGAGGCTGTCTCTTTGGATGAT 1194
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 CTCCGGGAGTCCCTCAGCTTCTACATCAGCCTGAATGACGAGGCTGTCTCTTTGGATGAT 780

Qy    1195 GCCTAG 1200
           ||||||
```

```
Db    781 GCCTAG 786


RESULT 3
AAC77202
ID   AAC77202 standard; cDNA; 837 BP.
XX
AC   AAC77202;
XX
DT   08-FEB-2001  (first entry)
XX
DE   Human ORFX ORF2757 polynucleotide sequence SEQ ID NO:5513.
XX
KW   Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
KW   vulnerary; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
KW   anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
KW   immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
KW   hypotensive; dermatological; immunosuppressive; antiinflammatory;
KW   antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
KW   antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
KW   neurodegenerative disorder; osteoarthritis; graft vs host disease;
KW   cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
KW   cholesterol ester storage; systemic lupus erythematosus; infection;
KW   severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
KW   allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
KW   bone damage; cartilage damage; antiinflammatory disease; coagulation;
KW   thrombosis; contraceptive; ss.
XX
OS   Homo sapiens.
XX
PN   WO200058473-A2.
XX
PD   05-OCT-2000.
XX
PF   31-MAR-2000; 2000WO-US08621.
XX
PR   31-MAR-1999;   99US-0127607.
PR   02-APR-1999;   99US-0127636.
PR   05-APR-1999;   99US-0127728.
PR   30-MAR-2000; 2000US-0540763.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Leach M;
XX
DR   WPI; 2000-602362/57.
DR   P-PSDB; AAB42993.
XX
PT   Novel nucleic acids and peptides derived from open reading frame X,
PT   useful for treating e.g. cancers, proliferative disorders,
PT   neurodegenerative disorders and cardiovascular disease -
XX
PS   Claim 5; Page 4692-4693; 5507pp; English.
XX
CC   AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
CC   which represent the human ORFX open reading frames 1 to 3161. The ORFX
CC   sequences have activities such as: cytostatic; hepatotropic; vulnerary;
CC   antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
CC   osteopathic; anticonvulsant; antiarthritic; immunosuppressant;
CC   immunostimulant; cardiant; thrombolytic; coagulant; vasotropic;
CC   antidiabetic; hypotensive; dermatological; immunosuppressive;
CC   antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;
CC   antithyroid; and antianaemic. The sequences can be used for determining
CC   the presence of or predisposition to, or preventing or treating
CC   pathological conditions associated with an ORFX-associated disorder. The
CC   nucleic acids can be used to express ORFX proteins in gene therapy
CC   vectors. The proteins and nucleic acids may be used to treat cancers,
CC   proliferative disorders, neurodegenerative disorders, osteoarthritis,
CC   graft vs host disease, cardiovascular disease, diabetes mellitus,
CC   hypertension, hypothyroidism, cholesterol ester storage, systemic lupus
CC   erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,
CC   bacterial or fungal infection, malaria, autoimmune disorders, asthma,
CC   allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,
CC   nocturnal haemoglobinuria, antiinflammatory disease; to enhance
CC   coagulation; to inhibit thrombosis; and as a contraceptive.
XX
SQ   Sequence 837 BP; 176 A; 254 C; 245 G; 160 T; 2 other;

  Query Match             28.6%;  Score 733;  DB 21;  Length 837;
  Best Local Similarity   99.8%;  Pred. No. 1.8e-265;
  Matches  833;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy    456 AAGCTTGAGTTCCTCTGTCCAAGGCCAGGGACCTGTGACCATGGAAGCAGAGAGAAGCAA 515
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      3 AAGCTTGAGTTCCTCTGTCCAAGGCCAGGGACCTGTGACCATGGAAGCAGAGAGAAGCAA 62

Qy    516 GGCCACAGCCGTGGCCCTGGGCAGTTTCCCGGCAGGTGGCCCGGCCGAGCTGTCGCTGAG 575
          |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||
Db     63 GGCCACAGCCGCGGCCCTGGGCAGTTTCCCGGCAGGTGGCCCGGCCGAGCTGTCGCTGAG 122

Qy    576 ACTCGGGGAGCCATTGACCATCGTCTCTGAGGATGGAGACTGGTGGACGGTGCTGTCTGA 635
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    123 ACTCGGGGAGCCATTGACCATCGTCTCTGAGGATGGAGACTGGTGGACGGTGCTGTCTGA 182

Qy    636 AGTCTCAGGCAGAGAGTATAACATCCCCAGCGTCCACGTGGCCAAAGTCTCCCATGGGTG 695
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    183 AGTCTCAGGCAGAGAGTATAACATCCCCAGCGTCCACGTGGCCAAAGTCTCCCATGGGTG 242

Qy    696 GCTGTATGAGGGCCTGAGCAGGGAGAAAGCAGAGGAACTGCTGTTGTTACCTGGGAACCC 755
          |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
Db    243 GCTGTATGAGGGCCTGAGCAGGGAGAAAGCAGAGGACCTGCTGTTGTTACCTGGGAACCC 302

Qy    756 TGGAGGGGCCTTCCTCATCCGGGAGAGCCAGACCAGGAGAGGCTCTTACTCTCTGTCAGT 815
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    303 TGGAGGGGCCTTCCTCATCCGGGAGAGCCAGACCAGGAGAGGCTCTTACTCTCTGTCAGT 362

Qy    816 CCGCCTCAGCCGCCCTGCATCCTGGGACCGGATCAGACACTACAGGATCCACTGCCTTGA 875
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    363 CCGCCTCAGCCGCCCTGCATCCTGGGACCGGATCAGACACTACAGGATCCACTGCCTTGA 422

Qy    876 CAATGGCTGGCTGTACATCTCACCGCGCCTCACCTTCCCCTCACTCCAGGCCCTGGTGGA 935
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    423 CAATGGCTGGCTGTACATCTCACCGCGCCTCACCTTCCCCTCACTCCAGGCCCTGGTGGA 482

Qy    936 CCATTACTCTGAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCA 995
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    483 CCATTACTCTGAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCA 542

Qy    996 GAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACC 1055
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    543 GAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACC 602

Qy   1056 ACTCAACTGGAAAGAGCTGGACAGCTCCCTCCTGTTTTCTGAAGCTGCCACAGGGGAGGA 1115
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    603 ACTCAACTGGAAAGAGCTGGACAGCTCCCTCCTGTTTTCTGAAGCTGCCACAGGGGAGGA 662

Qy   1116 GTCTCTTCTCAGTGAGGGTCTCCGGGAGTCCCTCAGCTTCTACATCAGCCTGAATGACGA 1175
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    663 GTCTCTTCTCAGTGAGGGTCTCCGGGAGTCCCTCAGCTTCTACATCAGCCTGAATGACGA 722

Qy   1176 GGCTGTCTCTTTGGATGATGCCTAGGCCCAAAGGAGAGGCCAAAAGGGAAACCAAGGCTG 1235
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    723 GGCTGTCTCTTTGGATGATGCCTAGGCCCAAAGGAGAGGCCAAAAGGGAAACCAAGGCTG 782

Qy   1236 CACACCTAGAACCCCAATTCAGCCTCCTGGGCACCCCAGAGGCAAGGCTGTGCAC 1290
          |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    783 CACACCTAGAACCCCAATTCAGCCTCCTGGGCACCCCAGAGGCAAGGCTGTGCAC 837


RESULT 4
AAK56376
ID   AAK56376 standard; cDNA; 705 BP.
XX
AC   AAK56376;
XX
DT   06-NOV-2001  (first entry)
```

XX
DE Human immune/haematopoietic antigen encoding cDNA SEQ ID NO:1436.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ss.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.

```
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
DR   P-PSDB; AAM83595.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis -
XX
PS   Claim 1; SEQ ID NO 1436; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence 705 BP; 185 A; 191 C; 161 G; 165 T; 3 other;

  Query Match             21.1%;  Score 542;  DB 22;  Length 705;
  Best Local Similarity   99.7%;  Pred. No. 8e-194;
  Matches  642;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy   1897 TCAGCTCACTGCAACCTCCATCTCCTGGATTCAAACAATTCTCCTGCCTCAGCCTCCAGA 1956
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     42 TCAGCTCACTGCAACCTCCATCTCCTGGATTCAAACAATTCTCCTGCCTCAGCCTCCAGA 101

Qy   1957 ATAGCTGGGATTACAGGCGTACACCACCATGCCTGGCTAATTTTTTTGTATTTTTAGTAG 2016
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    102 ATAGCTGGGATTACAGGCGTACACCACCATGCCTGGCTAATTTTTTTGTATTTTTAGTAG 161

Qy   2017 ACATGGGGTTTCACCACATTGGCCAGGCTGGTGTCGAACTCCTGACCTCAGGTGATCCAC 2076
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    162 ACATGGGGTTTCACCACATTGGCCAGGCTGGTGTCGAACTCCTGACCTCAGGTGATCCAC 221

Qy   2077 CCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACGGCACCCAGCCTAGCT 2136
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    222 CCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACGGCACCCAGCCTAGCT 281

Qy   2137 CTCAGATCTCTATTTCATTTTGTGGCTTACCATTCCCTAGCACACTGGCCTTGCCATCTT 2196
           ||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||
Db    282 CTCAGATCTCTATTTCATTTTGTGGCTTACCAWTCCCTAGCACACTGGCCTTGCCATCTT 341

Qy   2197 GTGGCCGAATAAAAAATAACACCTCTTAAGTCTAGCACACTGCAGTGAGGCCAGGCACCT 2256
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    342 GTGGCCGAATAAAAAATAACACCTCTTAAGTCTAGCACACTGCAGTGAGGCCAGGCACCT 401

Qy   2257 CAGTGCTGGGCAGGGGCATCAGAAGGTGCTAAGCCCTCTCTCCACAATGCCAAGACGGAG 2316
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    402 CAGTGCTGGGCAGGGGCATCAGAAGGTGCTAAGCCCTCTCTCCACAATGCCAAGACGGAG 461

Qy   2317 ACCACAGCCTACACCAAATCCAGCCCTTGATTTCCCTGCTGCCTCCATAAACAGAAAGAG 2376
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    462 ACCACAGCCTACACCAAATCCAGCCCTTGATTTCCCTGCTGCCTCCATAAACAGAAAGAG 521

Qy   2377 GTCTGCTGGATCCGCTAAGGGATCAGGGAGAGGAAGAAAGAGGGATGGGGTGGGAGGCAC 2436
           |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db    522 GTCTGCTGGATCCGCTAAGGGATCAGGGAGAGGAAGAAAGAGGGATRGGGTGGGAGGCAC 581

Qy   2437 CCCCTCCAGTGCTCCTACTGGTTCCCAAGCTACAGGTGGGGTGGGAAAGGCTTTATCAGG 2496
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    582 CCCCTCCAGTGCTCCTACTGGTTCCCAAGCTACAGGTGGGGTGGGAAAGGCTTTATCAGG 641

Qy   2497 TATCATCAACAGGTTCTCAATTAAAGATTTGATTTATTCAAGTA 2540
           |||||||||||||||||||||||||||||||||||||||||||
Db    642 TATCATCAACAGGTTCTCAATTAAAGATTTGATTTATTCAAGTA 685


RESULT 5
AAL44090
ID   AAL44090 standard; cDNA; 737 BP.
XX
AC   AAL44090;
XX
DT   03-OCT-2002  (first entry)
XX
DE   Mouse MARS short isoform protein coding sequence.
XX
KW   Mouse; gene; ss; gene therapy; modulator of antigen receptor signalling;
KW   MARS; tumour suppressor gene; Scr-like adaptor protein; SLAP;
KW   myeloid malignancy; acute myelogenous leukaemia; autoimmune disorder;
KW   immunosuppression; myeloproliferative disorder; breast cancer.
XX
OS   Mus sp.
XX
FH   Key             Location/Qualifiers
FT   CDS             1..633
FT                   /*tag= a
FT                   /product= "Mouse MARS short isoform protein"
XX
PN   WO200242452-A2.
XX
PD   30-MAY-2002.
XX
PF   26-NOV-2001; 2001WO-CA01662.
XX
PR   27-NOV-2000; 2000CA-2324663.
XX
PA   (HOSP-) HOSPITAL FOR SICK CHILDREN.
XX
PI   Mcglade JC,  Loreto MP;
XX
DR   WPI; 2002-566564/60.
DR   P-PSDB; AAO15458.
XX
PT   New isolated modulator of antigen receptor signaling protein or its
PT   fragment, useful for treating malignant disorders such as myeloid
PT   malignancies, autoimmune disorders and myeloproliferative disorders  -
XX
PS   Claim 9; Page 77; 110pp; English.
XX
CC   The invention comprises the amino acid and coding sequences of modulator
CC   of antigen receptor signalling (MARS) proteins. The MARS protein is a
CC   putative tumour suppressor gene and exhibits structural and sequence
CC   similarity to the Scr-like adaptor protein (SLAP). The MARS DNA and
CC   protein sequences of the invention are useful for the treatment of
CC   myeloid malignancies (e.g. acute myelogenous leukaemia) autoimmune
CC   disorders, immunosuppression, myeloproliferative disorders and
CC   malignancies related to the de-regulation of tyrosine kinases (e.g.
CC   breast cancer). The present cDNA sequence encodes a mouse MARS protein.
XX
SQ   Sequence 737 BP; 152 A; 219 C; 218 G; 148 T; 0 other;

  Query Match             20.8%;  Score 534;  DB 24;  Length 737;
  Best Local Similarity   100.0%;  Pred. No. 7.9e-191;
  Matches  534;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy    415 ATGGGAAGTCTGCCCAGCAGAAGAAAATCTCTGCCAAGCCCAAGCTTGAGTTCCTCTGTC 474
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 ATGGGAAGTCTGCCCAGCAGAAGAAAATCTCTGCCAAGCCCAAGCTTGAGTTCCTCTGTC 60

Qy    475 CAAGGCCAGGGACCTGTGACCATGGAAGCAGAGAGAAGCAAGGCCACAGCCGTGGCCCTG 534
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 CAAGGCCAGGGACCTGTGACCATGGAAGCAGAGAGAAGCAAGGCCACAGCCGTGGCCCTG 120

Qy    535 GGCAGTTTCCCGGCAGGTGGCCCGGCCGAGCTGTCGCTGAGACTCGGGGAGCCATTGACC 594
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 GGCAGTTTCCCGGCAGGTGGCCCGGCCGAGCTGTCGCTGAGACTCGGGGAGCCATTGACC 180

Qy    595 ATCGTCTCTGAGGATGGAGACTGGTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTAT 654
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 ATCGTCTCTGAGGATGGAGACTGGTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTAT 240

Qy    655 AACATCCCCAGCGTCCACGTGGCCAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGC 714
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 AACATCCCCAGCGTCCACGTGGCCAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGC 300

Qy    715 AGGGAGAAAGCAGAGGAACTGCTGTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATC 774
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 AGGGAGAAAGCAGAGGAACTGCTGTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATC 360

Qy    775 CGGGAGAGCCAGACCAGGAGAGGCTCTTACTCTCTGTCAGTCCGCCTCAGCCGCCCTGCA 834
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 CGGGAGAGCCAGACCAGGAGAGGCTCTTACTCTCTGTCAGTCCGCCTCAGCCGCCCTGCA 420

Qy    835 TCCTGGGACCGGATCAGACACTACAGGATCCACTGCCTTGACAATGGCTGGCTGTACATC 894
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 TCCTGGGACCGGATCAGACACTACAGGATCCACTGCCTTGACAATGGCTGGCTGTACATC 480

Qy    895 TCACCGCGCCTCACCTTCCCCTCACTCCAGGCCCTGGTGGACCATTACTCTGAG 948
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 TCACCGCGCCTCACCTTCCCCTCACTCCAGGCCCTGGTGGACCATTACTCTGAG 534
```

RESULT 6
AAS74750
ID AAS74750 standard; cDNA; 2049 BP.
XX
AC AAS74750;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #10554.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; ABG10563.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 1; SEQ ID No 10554; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AAS94564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 2049 BP; 479 A; 573 C; 551 G; 443 T; 3 other;

Query Match 17.6%; Score 452; DB 23; Length 2049;
Best Local Similarity 100.0%; Pred. No. 3.8e-160;
Matches 452; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    372 ATTTCCCTCGATGATGTGCTTCTGAGTGCTCTGCTGAGGAACAATGGGAAGTCTGCCCAG 431
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    922 ATTTCCCTCGATGATGTGCTTCTGAGTGCTCTGCTGAGGAACAATGGGAAGTCTGCCCAG 981

Qy    432 CAGAAGAAAATCTCTGCCAAGCCCAAGCTTGAGTTCCTCTGTCCAAGGCCAGGGACCTGT 491
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    982 CAGAAGAAAATCTCTGCCAAGCCCAAGCTTGAGTTCCTCTGTCCAAGGCCAGGGACCTGT 1041

Qy    492 GACCATGGAAGCAGAGAGAAGCAAGGCCACAGCCGTGGCCCTGGGCAGTTTCCCGGCAGG 551
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1042 GACCATGGAAGCAGAGAGAAGCAAGGCCACAGCCGTGGCCCTGGGCAGTTTCCCGGCAGG 1101

Qy    552 TGGCCCGGCCGAGCTGTCGCTGAGACTCGGGGAGCCATTGACCATCGTCTCTGAGGATGG 611
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1102 TGGCCCGGCCGAGCTGTCGCTGAGACTCGGGGAGCCATTGACCATCGTCTCTGAGGATGG 1161

Qy    612 AGACTGGTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTATAACATCCCCAGCGTCCA 671
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1162 AGACTGGTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTATAACATCCCCAGCGTCCA 1221

Qy    672 CGTGGCCAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGCAGGGAGAAAGCAGAGGA 731
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1222 CGTGGCCAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGCAGGGAGAAAGCAGAGGA 1281

Qy    732 ACTGCTGTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATCCGGGAGAGCCAGACCAG 791
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1282 ACTGCTGTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATCCGGGAGAGCCAGACCAG 1341

Qy    792 GAGAGGCTCTTACTCTCTGTCAGTCCGCCTCA 823
          ||||||||||||||||||||||||||||||||
Db   1342 GAGAGGCTCTTACTCTCTGTCAGTCCGCCTCA 1373
```

RESULT 7
AAS74748
ID AAS74748 standard; cDNA; 603 BP.
XX
AC AAS74748;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #10552.
XX

KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; ABG10561.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 1; SEQ ID No 10552; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AAS94564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 603 BP; 124 A; 189 C; 164 G; 126 T; 0 other;

Query Match 15.8%; Score 405; DB 23; Length 603;
Best Local Similarity 100.0%; Pred. No. 2e-142;
Matches 405; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    796 GGCTCTTACTCTCTGTCAGTCCGCCTCAGCCGCCCTGCATCCTGGGACCGGATCAGACAC 855
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    199 GGCTCTTACTCTCTGTCAGTCCGCCTCAGCCGCCCTGCATCCTGGGACCGGATCAGACAC 258

Qy    856 TACAGGATCCACTGCCTTGACAATGGCTGGCTGTACATCTCACCGCGCCTCACCTTCCCC 915
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    259 TACAGGATCCACTGCCTTGACAATGGCTGGCTGTACATCTCACCGCGCCTCACCTTCCCC 318

Qy    916 TCACTCCAGGCCCTGGTGGACCATTACTCTGAGCTGGCGGATGACATCTGCTGCCTACTC 975
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    319 TCACTCCAGGCCCTGGTGGACCATTACTCTGAGCTGGCGGATGACATCTGCTGCCTACTC 378

Qy    976 AAGGAGCCCTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCT 1035
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    379 AAGGAGCCCTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCT 438

Qy   1036 GTGACTGTGCAGAGGACACCACTCAACTGGAAAGAGCTGGACAGCTCCCTCCTGTTTTCT 1095
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    439 GTGACTGTGCAGAGGACACCACTCAACTGGAAAGAGCTGGACAGCTCCCTCCTGTTTTCT 498

Qy   1096 GAAGCTGCCACAGGGGAGGAGTCTCTTCTCAGTGAGGGTCTCCGGGAGTCCCTCAGCTTC 1155
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    499 GAAGCTGCCACAGGGGAGGAGTCTCTTCTCAGTGAGGGTCTCCGGGAGTCCCTCAGCTTC 558

Qy   1156 TACATCAGCCTGAATGACGAGGCTGTCTCTTTGGATGATGCCTAG 1200
          ||||||||||||||||||||||||||||||||||||||||||||
Db    559 TACATCAGCCTGAATGACGAGGCTGTCTCTTTGGATGATGCCTAG 603
```

RESULT 8
AAS74747/c
ID AAS74747 standard; cDNA; 445 BP.
XX
AC AAS74747;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #10551.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; ABG10560.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 1; SEQ ID No 10551; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AAS94564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 445 BP; 89 A; 112 C; 143 G; 101 T; 0 other;

Query Match 9.5%; Score 244; DB 23; Length 445;
Best Local Similarity 99.7%; Pred. No. 4.9e-82;
Matches 364; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

```
Qy      73 CTGGGCCTTCCCTCCCTGGCTCGGCTGTGCTTGGGAGGGTTCCCCAGTCCAGAATCCCTA 132
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     414 CTGGGCCTTCCCTCCCTGGCTCGGCTGTGCTTGGGAGGGTTCCCCAGTCCAGAATCCCTA 355

Qy     133 AGGAGCATGGGGCAGCTGATCCATCCCTGGTGTACAAACTGCTGACTGCAGACAGATGCT 192
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     354 AGGAGCATGGGGCAGCTGATCCATCCCTGGTGTACAAACTGCTGACTGCAGACAGATGCT 295

Qy     193 GAGCTACCCAAACCAACACCTAGCCTCTCCCTGAAGATCCTCCCAGGCTGAGAGAGT-TC 251
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db     294 GAGCTACCCAAACCAACACCTAGCCTCTCCCTGAAGATCCTCCCAGGCTGAGAGAGTATC 235

Qy     252 TGGGTGTCCTAGGACCAAGGACACTGGCAGACTTCCAGAAGGGCCCCCAAAGCCCTAACC 311
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     234 TGGGTGTCCTAGGACCAAGGACACTGGCAGACTTCCAGAAGGGCCCCCAAAGCCCTAACC 175

Qy     312 TGTCCAGCCAGAGCATGCGTCTCAGCAGAGCTGTCTTCCCAAGCCTTTGATGACAAACCA 371
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     174 TGTCCAGCCAGAGCATGCGTCTCAGCAGAGCTGTCTTCCCAAGCCTTTGATGACAAACCA 115

Qy     372 ATTTCCCTCGATGATGTGCTTCTGAGTGCTCTGCTGAGGAACAATGGGAAGTCTGCCCAG 431
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     114 ATTTCCCTCGATGATGTGCTTCTGAGTGCTCTGCTGAGGAACAATGGGAAGTCTGCCCAG 55

Qy     432 CAGAA 436
           |||||
Db      54 CAGAA 50
```

RESULT 9
AAK67918
ID AAK67918 standard; DNA; 273 BP.
XX
AC AAK67918;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:22730.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.

PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure; SEQ ID NO 22730; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 273 BP; 76 A; 68 C; 71 G; 58 T; 0 other;

Query Match 8.5%; Score 219; DB 22; Length 273;
Best Local Similarity 100.0%; Pred. No. 1.3e-72;
Matches 219; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2330 CCAAATCCAGCCCTTGATTTCCCTGCTGCCTCCATAAACAGAAAGAGGTCTGCTGGATCC 2389
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 55 CCAAATCCAGCCCTTGATTTCCCTGCTGCCTCCATAAACAGAAAGAGGTCTGCTGGATCC 114

Qy 2390 GCTAAGGGATCAGGGAGAGGAAGAAAGAGGGATGGGGTGGGAGGCACCCCCTCCAGTGCT 2449
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 115 GCTAAGGGATCAGGGAGAGGAAGAAAGAGGGATGGGGTGGGAGGCACCCCCTCCAGTGCT 174

Qy 2450 CCTACTGGTTCCCAAGCTACAGGTGGGGTGGGAAAGGCTTTATCAGGTATCATCAACAGG 2509
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 175 CCTACTGGTTCCCAAGCTACAGGTGGGGTGGGAAAGGCTTTATCAGGTATCATCAACAGG 234

Qy 2510 TTCTCAATTAAAGATTTGATTTATTCAAGTATGTGAAAA 2548
|||||||||||||||||||||||||||||||||||||
Db 235 TTCTCAATTAAAGATTTGATTTATTCAAGTATGTGAAAA 273

RESULT 10
AAS70181
ID AAS70181 standard; cDNA; 211 BP.
XX
AC AAS70181;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #5985.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; ABG05994.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 1; SEQ ID No 5985; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as

CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AAS94564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 211 BP; 50 A; 51 C; 72 G; 38 T; 0 other;

Query Match 7.5%; Score 192; DB 23; Length 211;
Best Local Similarity 100.0%; Pred. No. 1.8e-62;
Matches 192; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 605 AGGATGGAGACTGGTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTATAACATCCCCA 664
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 20 AGGATGGAGACTGGTGGACGGTGCTGTCTGAAGTCTCAGGCAGAGAGTATAACATCCCCA 79

Qy 665 GCGTCCACGTGGCCAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGCAGGGAGAAAG 724
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 80 GCGTCCACGTGGCCAAAGTCTCCCATGGGTGGCTGTATGAGGGCCTGAGCAGGGAGAAAG 139

Qy 725 CAGAGGAACTGCTGTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATCCGGGAGAGCC 784
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 140 CAGAGGAACTGCTGTTGTTACCTGGGAACCCTGGAGGGGCCTTCCTCATCCGGGAGAGCC 199

Qy 785 AGACCAGGAGAG 796
||||||||||||
Db 200 AGACCAGGAGAG 211

RESULT 11
ABA44128
ID ABA44128 standard; DNA; 432 BP.
XX
AC ABA44128;
XX
DT 01-FEB-2002 (first entry)
XX
DE Human breast cell single exon nucleic acid probe #2823.
XX
KW Human; microarray; single exon probe; gene expression; breast;
KW disease; cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200157271-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00662.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-496933/54.
XX
PT New spatially-addressable set of single exon nucleic acid probes,
PT useful for measuring gene expression in sample derived from human
PT breast, comprises number of single exon nucleic acid probes
XX
PS Claim 1; SEQ ID NO 2823; 327pp + sequence listing; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human breast and BT 474 cells. The method involves contacting
CC the probes with a collection of detectably labelled nucleic acids
CC derived from mRNA of human breast, and then measuring the label
CC bound to each probe of the microarray. The probes are useful for
CC verifying the expression of regions of genomic DNA predicted to
CC encode proteins. They are useful for gene discovery, and for
CC determining predisposition and/or prognosing breast disease. Gene
CC expression analysis is useful for assessing the toxicity of chemical
CC agents on cells. The microarray of this invention presents a far greater
CC diversity of probes for measuring gene expression, with far less bias
CC than expressed sequence tag microarrays. The method is suitable for
CC rapid production of functional information from genomic sequence. The
CC present sequence is a single exon nucleic acid probe of the invention.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

Query Match 5.2%; Score 134; DB 22; Length 432;
Best Local Similarity 100.0%; Pred. No. 8.8e-41;
Matches 134; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy 1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy 1066 AAAGAGCTGGACAG 1079
||||||||||||||
Db 390 AAAGAGCTGGACAG 403

RESULT 12
ABA54580
ID ABA54580 standard; DNA; 432 BP.
XX
AC ABA54580;
XX
DT 01-FEB-2002 (first entry)
XX
DE Human foetal liver single exon nucleic acid probe #2885.
XX
KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00669.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;

```
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 1; SEQ ID NO 2885; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a single exon nucleic acid
CC   probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

  Query Match             5.2%;  Score 134;  DB 22;  Length 432;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-41;
  Matches  134;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy    1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy    1066 AAAGAGCTGGACAG 1079
           ||||||||||||||
Db     390 AAAGAGCTGGACAG 403


RESULT 13
ABA24363
ID   ABA24363 standard; DNA; 432 BP.
XX
AC   ABA24363;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Probe #2829 for gene expression analysis in human heart cell sample.
XX
KW   Human; gene expression; heart; microarray; vascular system; probe;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00666.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts -
XX
PS   Claim 1; SEQ ID No 2829; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart. The
CC   present sequence is one such probe. The probes may be used for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from the human heart via microarrays. By measuring gene expression, the
CC   probes are useful for predicting, diagnosing, grading, staging,
CC   monitoring and prognosing diseases of the human heart and vascular system
CC   e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC   congenital heart disease.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

  Query Match             5.2%;  Score 134;  DB 22;  Length 432;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-41;
  Matches  134;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy    1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy    1066 AAAGAGCTGGACAG 1079
           ||||||||||||||
Db     390 AAAGAGCTGGACAG 403


RESULT 14
AAK02872
ID   AAK02872 standard; DNA; 432 BP.
XX
AC   AAK02872;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe SEQ ID NO: 2863.
XX
KW   Human; brain expressed exon; gene expression analysis; probe;
KW   microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW   epilepsy; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00667.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
```

PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains -
XX
PS Example 4; SEQ ID NO: 2863; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention.
XX
SQ Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

Query Match 5.2%; Score 134; DB 22; Length 432;
Best Local Similarity 100.0%; Pred. No. 8.8e-41;
Matches 134; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy   1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy   1066 AAAGAGCTGGACAG 1079
          ||||||||||||||
Db    390 AAAGAGCTGGACAG 403
```

RESULT 15
AAK28314
ID AAK28314 standard; DNA; 432 BP.
XX
AC AAK28314;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed single exon probe SEQ ID NO: 2871.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00668.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human bone marrow -
XX
PS Example 4; SEQ ID NO: 2871; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is one of
CC the probes of the invention.
XX
SQ Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

Query Match 5.2%; Score 134; DB 22; Length 432;
Best Local Similarity 100.0%; Pred. No. 8.8e-41;
Matches 134; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy   1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy   1066 AAAGAGCTGGACAG 1079
          ||||||||||||||
Db    390 AAAGAGCTGGACAG 403
```

RESULT 16
AAI12879
ID AAI12879 standard; DNA; 432 BP.
XX
AC AAI12879;
XX
DT 12-OCT-2001 (first entry)
XX
DE Probe #2812 for gene expression analysis in human cervical cell sample.
XX
KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00670.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human cervical epithelial cells -
XX
PS Claim 25; SEQ ID No 2812; 487pp; English.
XX
CC The present invention relates to human single exon nucleic acid probes
CC (SENP). The present sequence is one such probe. The SENPs are derived
CC from human HeLa cells. The SENPs can be used to produce a single exon
CC microarray, which can be used for measuring human gene expression in a
CC sample derived from human cervical epithelial cells. By measuring gene
CC expression, the probes are therefore useful in grading and/or staging
CC of diseases of the cervix, notably cervical cancer.
CC Note: The sequence data for this patent did not form part of the printed

```
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

  Query Match             5.2%;  Score 134;  DB 22;  Length 432;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-41;
  Matches  134;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy    1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy    1066 AAAGAGCTGGACAG 1079
           ||||||||||||||
Db     390 AAAGAGCTGGACAG 403


RESULT 17
AAI34236
ID   AAI34236 standard; DNA; 432 BP.
XX
AC   AAI34236;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Probe #2922 used to measure gene expression in human placenta sample.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00663.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human placenta -
XX
PS   Claim 25; SEQ ID No 2922; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP).
CC   The present sequence is one such probe. The probes are useful for
CC   producing a microarray for predicting, measuring and displaying gene
CC   expression in samples derived from human placenta. The probes are useful
CC   for antenatal diagnosis of human genetic disorders.
XX
SQ   Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

  Query Match             5.2%;  Score 134;  DB 22;  Length 432;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-41;
  Matches  134;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy    1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy    1066 AAAGAGCTGGACAG 1079
           ||||||||||||||
Db     390 AAAGAGCTGGACAG 403


RESULT 18
AAI02797
ID   AAI02797 standard; DNA; 432 BP.
XX
AC   AAI02797;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Probe #2788 used to measure gene expression in human breast sample.
XX
KW   Probe; human; breast disease; breast cancer; development disorder; ss;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US00661.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression
PT   in a human breast -
XX
PS   Claim 25; SEQ ID No 2788; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes.
CC   The present sequence is one such probe. The probes are useful for
CC   measuring human gene expression in a human breast sample, where the probe
CC   hybridises at high stringency to a nucleic acid expressed in the human
CC   breast. The probes are useful for predicting, diagnosing, grading,
CC   staging, monitoring and prognosing diseases of the human breast,
CC   particularly those diseases with polygenic aetiology. The diseases
CC   include: breast cancer, disorders of development, inflammatory diseases
CC   of the breast, fibrocystic changes, proliferative breast disease and
CC   non-carcinoma tumours.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

  Query Match             5.2%;  Score 134;  DB 22;  Length 432;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-41;
  Matches  134;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy     946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy    1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy    1066 AAAGAGCTGGACAG 1079
           ||||||||||||||
Db     390 AAAGAGCTGGACAG 403
```

```
RESULT 19
ABS02823
ID   ABS02823 standard; DNA; 432 BP.
XX
AC   ABS02823;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human genome-derived single exon probe from lung SEQ ID No 2814.
XX
KW   Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US00665.
XX
PR   04-FEB-2000; 2000US-180312P.
PR   26-MAY-2000; 2000US-207456P.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-234687P.
PR   27-SEP-2000; 2000US-236359P.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples -
XX
PS   Claim 1; SEQ ID No 2814; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of
CC   probes; the novel set of probes which hybridise at high stringency to a
CC   nucleic acid expressed in the human lung; measuring gene expression in a
CC   sample derived from human lung, comprising (a) contacting the array with
CC   a collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of
CC   the array; identifying exons in a eukaryotic genome, comprising
CC   (a) algorithmically predicting at least one exon from genomic sequences
CC   of the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene
CC   expression analysis, and for identifying exons in a gene, particularly
CC   using human lung derived mRNA and for the study of lung diseases
CC   such as asthma, lung cancer, chronic obstructive pulmonary disease
CC   (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary
CC   fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease,
CC   Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary
CC   haemosiderosis, pulmonary histiocytosis, lymphangioleiomyomtosis,
CC   pulmonary alveolar proteinosis, Karagener syndrome, fibrocystic
CC   pulmonary dysplasia, primary ciliary dyskinesis, pulmonary hypertension
CC   and hyaline membrane disease. The present sequence is a single exon
CC   probe of the invention.
CC   Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic
CC   format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 432 BP; 109 A; 115 C; 111 G; 97 T; 0 other;

  Query Match             5.2%;  Score 134;  DB 24;  Length 432;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-41;
  Matches  134;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     270 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 329

Qy    1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     330 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 389

Qy    1066 AAAGAGCTGGACAG 1079
           ||||||||||||||
Db     390 AAAGAGCTGGACAG 403
```

```
RESULT 20
AAI14520
ID   AAI14520 standard; DNA; 448 BP.
XX
AC   AAI14520;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Probe #4453 for gene expression analysis in human cervical cell sample.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00670.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
```

```
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human cervical epithelial cells -
XX
PS   Claim 25; SEQ ID No 4453; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP). The present sequence is one such probe. The SENPs are derived
CC   from human HeLa cells. The SENPs can be used to produce a single exon
CC   microarray, which can be used for measuring human gene expression in a
CC   sample derived from human cervical epithelial cells. By measuring gene
CC   expression, the probes are therefore useful in grading and/or staging
CC   of diseases of the cervix, notably cervical cancer.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 448 BP; 111 A; 120 C; 113 G; 104 T; 0 other;

  Query Match             5.2%;  Score 134;  DB 22;  Length 448;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-41;
  Matches  134;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     286 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 345

Qy    1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     346 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 405

Qy    1066 AAAGAGCTGGACAG 1079
           ||||||||||||||
Db     406 AAAGAGCTGGACAG 419


RESULT 21
ABS04499
ID   ABS04499 standard; DNA; 448 BP.
XX
AC   ABS04499;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human genome-derived single exon probe from lung SEQ ID No 4490.
XX
KW   Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US00665.
XX
PR   04-FEB-2000; 2000US-180312P.
PR   26-MAY-2000; 2000US-207456P.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-234687P.
PR   27-SEP-2000; 2000US-236359P.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples -
XX
PS   Claim 1; SEQ ID No 4490; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of
CC   probes; the novel set of probes which hybridise at high stringency to a
CC   nucleic acid expressed in the human lung; measuring gene expression in a
CC   sample derived from human lung, comprising (a) contacting the array with
CC   a collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of
CC   the array; identifying exons in a eukaryotic genome, comprising
CC   (a) algorithmically predicting at least one exon from genomic sequences
CC   of the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene
CC   expression analysis, and for identifying exons in a gene, particularly
CC   using human lung derived mRNA and for the study of lung diseases
CC   such as asthma, lung cancer, chronic obstructive pulmonary disease
CC   (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary
CC   fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease,
CC   Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary
CC   haemosiderosis, pulmonary histiocytosis, lymphangioleiomyomtosis,
CC   pulmonary alveolar proteinosis, Karagener syndrome, fibrocystic
CC   pulmonary dysplasia, primary ciliary dyskinesis, pulmonary hypertension
CC   and hyaline membrane disease. The present sequence is a single exon
CC   probe of the invention.
CC   Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic
CC   format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 448 BP; 111 A; 120 C; 113 G; 104 T; 0 other;

  Query Match             5.2%;  Score 134;  DB 24;  Length 448;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-41;
  Matches  134;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     946 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 1005
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     286 GAGCTGGCGGATGACATCTGCTGCCTACTCAAGGAGCCCTGTGTCCTGCAGAGGGCTGGC 345

Qy    1006 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 1065
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     346 CCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGTGCAGAGGACACCACTCAACTGG 405
```

```
Qy   1066 AAAGAGCTGGACAG 1079
          ||||||||||||||
Db    406 AAAGAGCTGGACAG 419
```

RESULT 22
AAC12486/c
ID AAC12486 standard; cDNA; 122 BP.
XX
AC AAC12486;
XX
DT 06-OCT-2000 (first entry)
XX
DE Human secreted protein 5' EST, SEQ ID NO: 16561.
XX
KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping; ss.
XX
OS Homo sapiens.
XX
PN EP1033401-A2.
XX
PD 06-SEP-2000.
XX
PF 21-FEB-2000; 2000EP-0200610.
XX
PR 26-FEB-1999; 99US-0122487.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Giordano J;
XX
DR WPI; 2000-500381/45.
XX
PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures -
XX
PS Claim 1; SEQ ID 16561; 71pp + CD-ROM; English.
XX
CC The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. No ORF has yet been conclusively
CC identified within the present sequence. The 5' ESTs were prepared from
CC total human RNAs or polyA+ RNAs derived from 30 different tissues. EST
CC sequences usually correspond mainly to the 3' untranslated region (UTR)
CC of the mRNA because they are often obtained from oligo-dT primed cDNA
CC libraries. Such ESTs are not well suited for isolating cDNA sequences
CC derived from the 5' ends of mRNAs and even in those cases where longer
CC cDNA sequences have been obtained, the full 5' UTR is rarely included.
CC 5' ESTs are derived from mRNAs with intact 5' ends and can therefore be
CC used to obtain full length cDNAs and genomic DNAs. 5' ESTs are also used
CC in diagnostic, forensic, gene therapy and chromosome mapping procedures.
CC They are used to obtain upstream regulatory sequences and to design
CC expression and secretion vectors.
XX
SQ Sequence 122 BP; 30 A; 28 C; 37 G; 26 T; 1 other;

Query Match 4.2%; Score 109; DB 21; Length 122;
Best Local Similarity 100.0%; Pred. No. 2.6e-31;
Matches 109; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy   1475 GGGGGGTCTGACCTAGTTAGTTCTTGAGTTTGGGGTTTCCAGTACCATCTGGATGCCCTG 1534
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 GGGGGGTCTGACCTAGTTAGTTCTTGAGTTTGGGGTTTCCAGTACCATCTGGATGCCCTG 62

Qy   1535 CCTGTTGAGCCCCATTCTACATCCCCACCATTAACCAGGCCCCACCCAC 1583
          ||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 CCTGTTGAGCCCCATTCTACATCCCCACCATTAACCAGGCCCCACCCAC 13
```

RESULT 23
ABA49284
ID ABA49284 standard; DNA; 96 BP.
XX
AC ABA49284;
XX
DT 01-FEB-2002 (first entry)
XX
DE Human breast cell single exon nucleic acid probe #7979.
XX
KW Human; microarray; single exon probe; gene expression; breast;
KW disease; cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200157271-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00662.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-496933/54.
XX
PT New spatially-addressable set of single exon nucleic acid probes,
PT useful for measuring gene expression in sample derived from human
PT breast, comprises number of single exon nucleic acid probes -
XX
PS Claim 4; SEQ ID NO 7979; 327pp + sequence listing; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human breast and BT 474 cells. The method involves contacting
CC the probes with a collection of detectably labelled nucleic acids
CC derived from mRNA of human breast, and then measuring the label
CC bound to each probe of the microarray. The probes are useful for
CC verifying the expression of regions of genomic DNA predicted to
CC encode proteins. They are useful for gene discovery, and for
CC determining predisposition and/or prognosing breast disease. Gene
CC expression analysis is useful for assessing the toxicity of chemical
CC agents on cells. The microarray of this invention presents a far greater
CC diversity of probes for measuring gene expression, with far less bias
CC than expressed sequence tag microarrays. The method is suitable for
CC rapid production of functional information from genomic sequence. The
CC present sequence is a single exon nucleic acid probe of the invention.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

Query Match 3.7%; Score 96; DB 22; Length 96;
Best Local Similarity 100.0%; Pred. No. 2e-26;
Matches 96; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy   1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
          ||||||||||||||||||||||||||||||||||||
Db     61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96
```

```
RESULT 24
ABA67198
ID   ABA67198 standard; DNA; 96 BP.
XX
AC   ABA67198;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Human foetal liver single exon nucleic acid probe #15503.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00669.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 4; SEQ ID NO 15503; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a single exon nucleic acid
CC   probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

  Query Match             3.7%;  Score 96;  DB 22;  Length 96;
  Best Local Similarity   100.0%;  Pred. No. 2e-26;
  Matches   96;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy   1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
          |||||||||||||||||||||||||||||||||||
Db     61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96


RESULT 25
ABA34292
ID   ABA34292 standard; DNA; 96 BP.
XX
AC   ABA34292;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Probe #12758 for gene expression analysis in human heart cell sample.
XX
KW   Human; gene expression; heart; microarray; vascular system; probe;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00666.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts -
XX
PS   Claim 4; SEQ ID No 12758; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart. The
CC   present sequence is one such probe. The probes may be used for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from the human heart via microarrays. By measuring gene expression, the
CC   probes are useful for predicting, diagnosing, grading, staging,
CC   monitoring and prognosing diseases of the human heart and vascular system
CC   e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC   congenital heart disease.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

  Query Match             3.7%;  Score 96;  DB 22;  Length 96;
  Best Local Similarity   100.0%;  Pred. No. 2e-26;
  Matches   96;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy   1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
          |||||||||||||||||||||||||||||||||||
Db     61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96


RESULT 26
AAK15640
ID   AAK15640 standard; DNA; 96 BP.
XX
AC   AAK15640;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe SEQ ID NO: 15631.
XX
KW   Human; brain expressed exon; gene expression analysis; probe;
KW   microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW   epilepsy; cancer; ss.
```

XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00667.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains -
XX
PS Example 4; SEQ ID NO: 15631; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention.
XX
SQ Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

Query Match 3.7%; Score 96; DB 22; Length 96;
Best Local Similarity 100.0%; Pred. No. 2e-26;
Matches 96; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy 1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
||||||||||||||||||||||||||||||||||
Db 61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96

RESULT 27
AAK41374
ID AAK41374 standard; DNA; 96 BP.
XX
AC AAK41374;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed single exon probe SEQ ID NO: 15931.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00668.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human bone marrow -
XX
PS Example 4; SEQ ID NO: 15931; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is one of
CC the probes of the invention.
XX
SQ Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

Query Match 3.7%; Score 96; DB 22; Length 96;
Best Local Similarity 100.0%; Pred. No. 2e-26;
Matches 96; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy 1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
||||||||||||||||||||||||||||||||||
Db 61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96

RESULT 28
AAI22119
ID AAI22119 standard; DNA; 96 BP.
XX
AC AAI22119;
XX
DT 12-OCT-2001 (first entry)
XX
DE Probe #12052 for gene expression analysis in human cervical cell sample.
XX
KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00670.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX

```
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human cervical epithelial cells -
XX
PS   Claim 25; SEQ ID No 12052; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP). The present sequence is one such probe. The SENPs are derived
CC   from human HeLa cells. The SENPs can be used to produce a single exon
CC   microarray, which can be used for measuring human gene expression in a
CC   sample derived from human cervical epithelial cells. By measuring gene
CC   expression, the probes are therefore useful in grading and/or staging
CC   of diseases of the cervix, notably cervical cancer.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

  Query Match             3.7%;  Score 96;  DB 22;  Length 96;
  Best Local Similarity   100.0%;  Pred. No. 2e-26;
  Matches   96;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy   1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
          |||||||||||||||||||||||||||||||||||
Db     61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96


RESULT 29
AAI47414
ID   AAI47414 standard; DNA; 96 BP.
XX
AC   AAI47414;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Probe #16100 used to measure gene expression in human placenta sample.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00663.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488B97/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human placenta -
XX
PS   Claim 25; SEQ ID No 16100; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP).
CC   The present sequence is one such probe. The probes are useful for
CC   producing a microarray for predicting, measuring and displaying gene
CC   expression in samples derived from human placenta. The probes are useful
CC   for antenatal diagnosis of human genetic disorders.
XX
SQ   Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

  Query Match             3.7%;  Score 96;  DB 22;  Length 96;
  Best Local Similarity   100.0%;  Pred. No. 2e-26;
  Matches   96;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy   1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
          |||||||||||||||||||||||||||||||||||
Db     61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96


RESULT 30
AAI07818
ID   AAI07818 standard; DNA; 96 BP.
XX
AC   AAI07818;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Probe #7809 used to measure gene expression in human breast sample.
XX
KW   Probe; human; breast disease; breast cancer; development disorder; ss;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US00661.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression
PT   in a human breast -
XX
PS   Claim 25; SEQ ID No 7809; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes.
CC   The present sequence is one such probe. The probes are useful for
CC   measuring human gene expression in a human breast sample, where the probe
CC   hybridises at high stringency to a nucleic acid expressed in the human
CC   breast. The probes are useful for predicting, diagnosing, grading,
CC   staging, monitoring and prognosing diseases of the human breast,
CC   particularly those diseases with polygenic aetiology. The diseases
CC   include: breast cancer, disorders of development, inflammatory diseases
CC   of the breast, fibrocystic changes, proliferative breast disease and
CC   non-carcinoma tumours.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
```

CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

Query Match 3.7%; Score 96; DB 22; Length 96;
Best Local Similarity 100.0%; Pred. No. 2e-26;
Matches 96; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy 1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
|||||||||||||||||||||||||||||||||||
Db 61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96

RESULT 31
ABS15380
ID ABS15380 standard; DNA; 96 BP.
XX
AC ABS15380;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human genome-derived single exon probe ORF from lung SEQ ID No 15371.
XX
KW Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesis; pulmonary hypertension;
KW hyaline membrane disease; open reading frame; ORF.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US00665.
XX
PR 04-FEB-2000; 2000US-180312P.
PR 26-MAY-2000; 2000US-207456P.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples -
XX
PS Claim 4; SEQ ID No 15371; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of
CC probes; the novel set of probes which hybridise at high stringency to a
CC nucleic acid expressed in the human lung; measuring gene expression in a
CC sample derived from human lung, comprising (a) contacting the array with
CC a collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of
CC the array; identifying exons in a eukaryotic genome, comprising
CC (a) algorithmically predicting at least one exon from genomic sequences
CC of the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene
CC expression analysis, and for identifying exons in a gene, particularly
CC using human lung derived mRNA and for the study of lung diseases
CC such as asthma, lung cancer, chronic obstructive pulmonary disease
CC (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary
CC fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease,
CC Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary
CC haemosiderosis, pulmonary histiocytosis, lymphangioleiomyomtosis,
CC pulmonary alveolar proteinosis, Karagener syndrome, fibrocystic
CC pulmonary dysplasia, primary ciliary dyskinesis, pulmonary hypertension
CC and hyaline membrane disease. The present sequence is a single exon
CC probe open reading frame of the invention.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 96 BP; 22 A; 29 C; 28 G; 17 T; 0 other;

Query Match 3.7%; Score 96; DB 24; Length 96;
Best Local Similarity 100.0%; Pred. No. 2e-26;
Matches 96; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 984 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 1043
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 CTGTGTCCTGCAGAGGGCTGGCCCGCTCCCTGGCAAGGATATACCCCTACCTGTGACTGT 60

Qy 1044 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 1079
|||||||||||||||||||||||||||||||||||
Db 61 GCAGAGGACACCACTCAACTGGAAAGAGCTGGACAG 96

RESULT 32
AAK89725/c
ID AAK89725 standard; DNA; 361 BP.
XX
AC AAK89725;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human digestive system antigen genomic sequence SEQ ID NO: 3301.
XX
KW Human; digestive system antigen; gene therapy; cancer; appendicitis;
KW ulcerative colitis; infection; Hirschsprung's disease; chronic colitis;
KW digestive system disorder; Meckel's diverticulum; ds.
XX
OS Homo sapiens.
XX
PN WO200155314-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01324.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.

PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-502630/55.
XX
PT Polynucleotides encoding digestive system antigens, useful for
PT diagnosing, treating, preventing and/or prognozing disorders of the
PT digestive system, particularly cancer and cancer metastases -
XX
PS Disclosure; SEQ ID NO 3301; 986pp; English.
XX
CC The present invention provides the protein and coding sequences of a

CC number of human digestive system antigens. These can be used in the
CC diagnosis, treatment and prevention of digestive system disorders,
CC including cancer, Meckel's diverticulum, bacterial or parasitic
CC infections, appendicitis, Hirschsprung's disease, chronic colitis or
CC ulcerative colitis. The present sequence is a genomic DNA fragment
CC encoding a digestive system antigen of the invention.
XX
SQ Sequence 361 BP; 86 A; 90 C; 88 G; 97 T; 0 other;

Query Match 2.8%; Score 71; DB 22; Length 361;
Best Local Similarity 100.0%; Pred. No. 3.9e-17;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy   2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    295 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 236

Qy   2110 GTGTGAGCCAC 2120
          ||||||||||||
Db    235 GTGTGAGCCAC 225
```

RESULT 33
AAL07037/c
ID AAL07037 standard; DNA; 373 BP.
XX
AC AAL07037;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human reproductive system related antigen DNA SEQ ID NO: 9725.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200155320-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01339.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.

PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 9725; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 373 BP; 115 A; 69 C; 98 G; 91 T; 0 other;

Query Match 2.7%; Score 69; DB 22; Length 373;
Best Local Similarity 100.0%; Pred. No. 2.2e-16;
Matches 69; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2052 GAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGT 2111
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 342 GAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGT 283

Qy 2112 GTGAGCCAC 2120
|||||||||
Db 282 GTGAGCCAC 274

RESULT 34
AAI62715/c
ID AAI62715 standard; DNA; 373 BP.
XX
AC AAI62715;
XX
DT 19-OCT-2001 (first entry)
XX
DE Human breast or ovarian antigen genomic DNA SEQ ID NO: 365.
XX
KW Human; breast antigen; ovarian antigen; cancer; metastasis; gene therapy;
KW ds.
XX
OS Homo sapiens.
XX
PN WO200155324-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01344.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.

PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488785/53.
XX
PT New isolated nucleic acids and polypeptides, useful for diagnosing,
PT treating and/or preventing human diseases and disorders -
XX
PS Disclosure; SEQ ID NO: 365; 520pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of ovarian and breast antigens. These are shown in
CC AAI62467-AAI62572 and AAM42240-AAM42345. The sequences can be used in the
CC diagnosis, prevention and treatment of breast and ovarian cancers, and
CC their metastases. The present sequence is a genomic sequence of the
CC invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 373 BP; 115 A; 69 C; 98 G; 91 T; 0 other;

Query Match 2.7%; Score 69; DB 22; Length 373;
Best Local Similarity 100.0%; Pred. No. 2.2e-16;
Matches 69; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2052 GAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGT 2111
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 342 GAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGT 283

Qy 2112 GTGAGCCAC 2120
|||||||||
Db 282 GTGAGCCAC 274

RESULT 35
AAH09392
ID AAH09392 standard; cDNA; 579 BP.
XX
AC AAH09392;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human cDNA clone (3'-primer) SEQ ID NO:6227.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-0116126.
XX
PR 29-JUL-1999; 99JP-0248036.
PR 27-AUG-1999; 99JP-0300253.
PR 11-JAN-2000; 2000JP-0118776.
PR 02-MAY-2000; 2000JP-0183767.
PR 09-JUN-2000; 2000JP-0241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI; 2001-318749/34.

```
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 3; SEQ ID 6227; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence 579 BP; 146 A; 133 C; 111 G; 181 T; 8 other;

  Query Match             2.5%;  Score 65;  DB 22;  Length 579;
  Best Local Similarity   100.0%;  Pred. No. 6.3e-15;
  Matches   65;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy   2056 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2115
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    329 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 388

Qy   2116 GCCAC 2120
           |||||
Db    389 GCCAC 393


RESULT 36
AAH17124/c
ID   AAH17124 standard; cDNA; 1729 BP.
XX
AC   AAH17124;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human cDNA sequence SEQ ID NO:16457.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 8; SEQ ID 16457; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence 1729 BP; 567 A; 301 C; 377 G; 484 T; 0 other;

  Query Match             2.5%;  Score 65;  DB 22;  Length 1729;
  Best Local Similarity   100.0%;  Pred. No. 5.3e-15;
  Matches   65;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy   2056 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2115
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1401 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 1342

Qy   2116 GCCAC 2120
           |||||
Db   1341 GCCAC 1337


RESULT 37
AAL35819
ID   AAL35819 standard; DNA; 12541 BP.
XX
AC   AAL35819;
XX
DT   08-JAN-2002  (first entry)
XX
DE   Human musculoskeletal system related polynucleotide SEQ ID NO 2184.
XX
KW   Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW   antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW   vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW   cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW   neurological disease; infection; human; secreted protein;
KW   musculoskeletal system; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155367-A1.
XX
PD   02-AUG-2001.
```

XX
PF 17-JAN-2001; 2001WO-US01338.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-451937/48.
XX

PT Isolated polypeptide for treating, preventing and/ or prognosing
PT disorders related to the musculoskeletal system including
PT musculoskeletal cancers and also for testing and detection e.g.
PT diagnosis -
XX
PS Example 2; SEQ ID NO 2184; 781pp + Sequence Listing; English.
XX
CC The invention relates to novel genes (AAL34669-AAL37666) and proteins
CC (ABB03087-ABB04109) associated with the musculoskeletal system useful
CC for preventing, treating or ameliorating medical conditions e.g. by
CC protein or gene therapy. The genes are isolated from a range of human
CC tissues disclosed in the specification. The nucleic acids, proteins,
CC antibodies and (ant)agonists are useful in the diagnosis, treatment
CC and prevention of: (a) cancer, e.g. breast and ovarian cancer and
CC other cancers of the adrenal gland, bone, bone marrow, breast,
CC gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis;
CC (c) cardiovascular disorders such as myocardial ischaemias; (d) wound
CC healing; (e) neurological diseases e.g. cerebral anoxia and epilepsy;
CC and (f) infectious diseases such as viral, bacterial, fungal and
CC parasitic infections.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12541 BP; 3758 A; 2069 C; 2875 G; 3839 T; 0 other;

Query Match 2.5%; Score 65; DB 22; Length 12541;
Best Local Similarity 100.0%; Pred. No. 3.8e-15;
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2052 GAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGT 2111
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4886 GAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGT 4945

Qy 2112 GTGAG 2116
|||||
Db 4946 GTGAG 4950

RESULT 38
AAL05944
ID AAL05944 standard; DNA; 13467 BP.
XX
AC AAL05944;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human reproductive system related antigen DNA SEQ ID NO: 8632.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200155320-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01339.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.

PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 8632; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 13467 BP; 3228 A; 3445 C; 3232 G; 3562 T; 0 other;

Query Match 2.5%; Score 65; DB 22; Length 13467;
Best Local Similarity 100.0%; Pred. No. 3.8e-15;
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2056 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2115
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2566 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2625

Qy 2116 GCCAC 2120
|||||
Db 2626 GCCAC 2630

RESULT 39
AAS27670
ID AAS27670 standard; DNA; 13467 BP.
XX
AC AAS27670;
XX
DT 07-NOV-2001 (first entry)
XX
DE DNA encoding novel signal transduction pathway protein, Seq ID 1330.
XX
KW Neuroprotective; cytostatic; dermatological; immunosuppressive; tumour;
KW antiinflammatory; anti-HIV; antibacterial; antiinflammatory; cancer;
KW immune system disorder; rheumatoid arthritis; inflammatory condition;
KW organ transplant rejection; infection; hepatitis C; blood disorder;
KW sickle cell anaemia; hyperproliferative disorder; Gaucher's disease;
KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW chromosomal abnormality; Down syndrome; ischaemia; renal disorder;
KW cardiovascular; respiratory; wound healing; endocrine; Addison's disease;
KW reproductive system; gastrointestinal; liver disorder; AIDS; ds;
KW acquired immune deficiency syndrome.
XX
OS Homo sapiens.
XX
PN WO200154733-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01312.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.

PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465460/50.
XX
PT Novel polypeptides useful for diagnosing, treating, preventing and/or
PT prognosing disorders related to the proteins, including cancers, immune
PT disorders and neuronal disorders -
XX
PS Claim 1; SEQ ID No 1330; 880pp; English.
XX
CC The invention relates to novel isolated polypeptides (I), and
CC polynucleotides (II). (I), (II) and the antibody to (I) are useful for
CC diagnosing, preventing and treating diseases including immune system
CC disorders (e.g. congenital and acquired immunodeficiencies, autoimmune
CC disorders (e.g rheumatoid arthritis), inflammatory conditions, organ
CC transplant rejections and graft versus host disease, infectious diseases
CC (e.g. hepatitis C), bleeding disorders, haemoglobin abnormalities and
CC other blood-related disorders (sickle cell anaemia), myeloproliferative
CC disorders, primary haematopoietic disorders, hyperproliferative
CC disorders (e.g. Gaucher's disease and cancer), neurodegenerative
CC disorders (e.g. Alzheimer's disease, Parkinson's disease), chromosomal
CC abnormalities (Down syndrome), ischaemic injury (e.g. stroke), renal
CC disorders (e.g. glomerulonephritis), cardiovascular disorders
CC (e.g. arrhythmia), respiratory disorders, dermatological disorders, in
CC wound healing, epithelial cell proliferation, endocrine disorders (e.g.
CC Addison's disease), reproductive system disorders, gastrointestinal
CC disorder (inflammatory disorders), liver disorders (cirrhosis),
CC as stimulators of B-cell responsiveness to pathogens, activators of
CC T-cells, to induce higher affinity antibodies, and as a means to induce
CC tumour proliferation in pathologies e.g. acquired immune deficiency
CC syndrome (AIDS). AAS26976-AAS27850 represent novel signal transduction
CC pathway protein coding sequences and PCR primers of the invention.
XX
SQ Sequence 13467 BP; 3228 A; 3445 C; 3232 G; 3562 T; 0 other;

Query Match 2.5%; Score 65; DB 22; Length 13467;
Best Local Similarity 100.0%; Pred. No. 3.8e-15;
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy   2056 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2115
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   2566 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2625

Qy   2116 GCCAC 2120
          |||||
Db   2626 GCCAC 2630


RESULT 40
AAS27838
ID   AAS27838 standard; DNA; 13467 BP.
XX
AC   AAS27838;
XX
DT   07-NOV-2001  (first entry)
XX
DE   DNA encoding novel signal transduction pathway protein, Seq ID 1498.
XX
KW   Neuroprotective; cytostatic; dermatological; immunosuppressive; tumour;
KW   antiinflammatory; anti-HIV; antibacterial; antiinflammatory; cancer;
KW   immune system disorder; rheumatoid arthritis; inflammatory condition;
KW   organ transplant rejection; infection; hepatitis C; blood disorder;
KW   sickle cell anaemia; hyperproliferative disorder; Gaucher's disease;
KW   neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW   chromosomal abnormality; Down syndrome; ischaemia; renal disorder;
KW   cardiovascular; respiratory; wound healing; endocrine; Addison's disease;
KW   reproductive system; gastrointestinal; liver disorder; AIDS; ds;
KW   acquired immune deficiency syndrome.
XX
OS   Homo sapiens.
XX
PN   WO200154733-A1.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01312.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
```

```
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-465460/50.
XX
PT   Novel polypeptides useful for diagnosing, treating, preventing and/or
PT   prognosing disorders related to the proteins, including cancers, immune
PT   disorders and neuronal disorders  -
XX
PS   Claim 1; SEQ ID No 1498; 880pp; English.
XX
CC   The invention relates to novel isolated polypeptides (I), and
CC   polynucleotides (II). (I), (II) and the antibody to (I) are useful for
CC   diagnosing, preventing and treating diseases including immune system
CC   disorders (e.g. congenital and acquired immunodeficiencies, autoimmune
CC   disorders (e.g rheumatoid arthritis), inflammatory conditions, organ
CC   transplant rejections and graft versus host disease, infectious diseases
CC   (e.g. hepatitis C), bleeding disorders, haemoglobin abnormalities and
CC   other blood-related disorders (sickle cell anaemia), myeloproliferative
CC   disorders, primary haematopoietic disorders, hyperproliferative
CC   disorders (e.g. Gaucher's disease and cancer), neurodegenerative
CC   disorders (e.g. Alzheimer's disease, Parkinson's disease), chromosomal
CC   abnormalities (Down syndrome), ischaemic injury (e.g. stroke), renal
CC   disorders (e.g. glomerulonephritis), cardiovascular disorders
CC   (e.g. arrhythmia), respiratory disorders, dermatological disorders, in
CC   wound healing, epithelial cell proliferation, endocrine disorders (e.g.
CC   Addison's disease), reproductive system disorders, gastrointestinal
CC   disorder (inflammatory disorders), liver disorders (cirrhosis),
CC   as stimulators of B-cell responsiveness to pathogens, activators of
CC   T-cells, to induce higher affinity antibodies, and as a means to induce
CC   tumour proliferation in pathologies e.g. acquired immune deficiency
CC   syndrome (AIDS). AAS26976-AAS27850 represent novel signal transduction
CC   pathway protein coding sequences and PCR primers of the invention.
XX
SQ   Sequence 13467 BP; 3228 A; 3445 C; 3232 G; 3562 T; 0 other;

  Query Match             2.5%;  Score 65;  DB 22;  Length 13467;
  Best Local Similarity   100.0%;  Pred. No. 3.8e-15;
  Matches   65;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy   2056 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2115
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   2566 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2625

Qy   2116 GCCAC 2120
          |||||
Db   2626 GCCAC 2630

RESULT 41
AAK85539
ID   AAK85539 standard; DNA; 13467 BP.
XX
AC   AAK85539;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen genomic sequence SEQ ID NO:40351.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01354.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
```

PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure; SEQ ID NO 40351; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 13467 BP; 3228 A; 3445 C; 3232 G; 3562 T; 0 other;

Query Match 2.5%; Score 65; DB 22; Length 13467;
Best Local Similarity 100.0%; Pred. No. 3.8e-15;
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2056 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2115
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2566 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2625

Qy 2116 GCCAC 2120
|||||
Db 2626 GCCAC 2630

RESULT 42
ABL98508
ID ABL98508 standard; DNA; 13467 BP.
XX
AC ABL98508;
XX
DT 21-JUN-2002 (first entry)
XX
DE Human testicular antigen encoding DNA fragment SEQ ID NO: 3160.

XX
KW Human; testicular antigen; testes; cancer; metastasis; immune disorder;
KW reproductive system disorder; urinary system disorder; gene therapy;
KW cardiovascular disorder; respiratory disorder; neurological disorder;
KW gastrointestinal disease; infection; cytostatic; gene; ds.
XX
OS Homo sapiens.
XX
PN WO200155317-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01329.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.

PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483232/52.
XX
PT Nucleic acids encoding 973 human testicular antigen polypeptides,
PT useful for preventing, diagnosing and/or treating testicular cancer -
XX
PS Disclosure; SEQ ID NO 3160; 766pp; English.
XX
CC The present invention provides the protein and coding sequences of 973
CC human testicular antigens, and fragments of their genomic sequences. The
CC sequences can be used in the treatment of cardiovascular, urinary system,
CC reproductive system, immune, respiratory, neurological and
CC gastrointestinal disorders, infections, and particularly cancer,
CC especially testicular cancers. The present sequence is a DNA encoding a
CC protein fragment of the invention.
XX
SQ Sequence 13467 BP; 3228 A; 3445 C; 3232 G; 3562 T; 0 other;

Query Match 2.5%; Score 65; DB 23; Length 13467;
Best Local Similarity 100.0%; Pred. No. 3.8e-15;
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2056 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2115
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2566 TCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGA 2625

Qy 2116 GCCAC 2120
|||||
Db 2626 GCCAC 2630

RESULT 43
AAZ24851/c
ID AAZ24851 standard; DNA; 749 BP.
XX
AC AAZ24851;
XX
DT 02-DEC-1999 (first entry)
XX
DE Human secreted protein gene 41 clone HTWKG71.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Homo sapiens.
XX
PN WO9947540-A1.
XX
PD 23-SEP-1999.
XX
PF 18-MAR-1999; 99WO-US05804.
XX
PR 19-MAR-1998; 98US-0078563.
PR 19-MAR-1998; 98US-0078566.
PR 19-MAR-1998; 98US-0078573.
PR 19-MAR-1998; 98US-0078574.
PR 19-MAR-1998; 98US-0078576.
PR 19-MAR-1998; 98US-0078577.
PR 19-MAR-1998; 98US-0078578.
PR 19-MAR-1998; 98US-0078579.
PR 19-MAR-1998; 98US-0078581.
PR 01-APR-1998; 98US-0080312.
PR 01-APR-1998; 98US-0080313.
PR 01-APR-1998; 98US-0080314.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J, Rosen CA, Yu G, Young PE, Feng P, Soppet DR;
PI Wei Y, Endress GA, Duan RD, Kyaw H, Ebner R, Lafleur DW;
PI Olsen HS, Shi Y, Moore PA;
XX
DR WPI; 1999-562050/47.
DR P-PSDB; AAY41348.
XX
PT New isolated human genes, useful for diagnosis and treatment of e.g.
PT cancers, neurological disorders, immune diseases, inflammation or blood
PT disorders -
XX
PS Claim 1; Page 323; 484pp; English.
XX
CC This sequence represents a nucleic acid molecule which encodes a
CC secreted human protein. The gene number, and the clone it is derived
CC from, are detailed in the descriptor line. The gene can be used to
CC generate fusion proteins by linking to the gene to a human immunoglobulin
CC Fc portion (e.g. AAZ24802) for increasing the stability of the fused
CC protein as compared to the human protein only.
CC The invention relates to 95 novel genes and their fragments (nucleic
CC acid sequences: AAZ24811-Z24907; amino acid sequences AAY41308-Y41404)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein or gene therapy. Also, pathological
CC conditions can be diagnosed by determining the amount of the new
CC polypeptides in a sample or by determining the presence of mutations in
CC the new polynucleotides. Specific uses are described for each of the 95
CC polynucleotides, based on which tissues they are most highly expressed in
CC (see AAZ24811 for described uses).
XX
SQ Sequence 749 BP; 223 A; 151 C; 190 G; 184 T; 1 other;

Query Match 2.5%; Score 64; DB 20; Length 749;
Best Local Similarity 100.0%; Pred. No. 1.4e-14;
Matches 64; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 495 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 436

Qy 2110 GTGT 2113
||||
Db 435 GTGT 432

RESULT 44
AAK72555
ID AAK72555 standard; DNA; 23989 BP.
XX
AC AAK72555;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:27367.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX

PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -

XX
PS Disclosure; SEQ ID NO 27367; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 23989 BP; 5695 A; 6370 C; 6054 G; 5870 T; 0 other;

Query Match 2.5%; Score 64; DB 22; Length 23989;
Best Local Similarity 100.0%; Pred. No. 8.1e-15;
Matches 64; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2057 CCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAG 2116
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 14731 CCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAG 14790

Qy 2117 CCAC 2120
||||
Db 14791 CCAC 14794

RESULT 45
ABK83567
ID ABK83567 standard; cDNA; 112460 BP.
XX
AC ABK83567;
XX
DT 14-AUG-2002 (first entry)
XX
DE Human cDNA differentially expressed in granulocytic cells #138.
XX
KW Human; ss; granulocytic cell; DNA chip; bacterial infection;
KW viral infection; parasitic infection; protozoal infection;
KW fungal infection; sterile inflammatory disease; psoriasis;
KW rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KW cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW adult respiratory distress syndrome; inflammatory bowel disease;
KW Crohn's disease; ulcerative colitis; periodontal disease;
KW granulocyte activation; chronic inflammation; allergy.
XX
OS Homo sapiens.
XX
PN WO200228999-A2.
XX
PD 11-APR-2002.
XX
PF 03-OCT-2001; 2001WO-US30821.
XX
PR 03-OCT-2000; 2000US-237189P.
XX
PA (GENE-) GENE LOGIC INC.
XX
PI Beazer-Barclay Y, Weissman SM, Yamaga S, Vockley J;
XX
DR WPI; 2002-435328/46.
XX
PT Detecting granulocyte activation by detecting differential expression
PT of genes associated with granulocyte activation, which serves as
PT diagnostic markers that is useful for monitoring disease states and
PT drug toxicity -
XX
PS Claim 1; SEQ ID No 138; 114pp; English.
XX
CC The invention relates to detecting (M1) granulocyte (GC) activation
CC (GCA), by detecting the level of expression of gene(s) (Gs) identified by
CC DNA chip analysis as given in the specification, and comparing
CC the expression level to an expression level in an unactivated
CC GC, where differential expression of Gs is indicative of GCA.
CC Also included are modulating (M2) GA by contacting GC with an agent
CC that alters the expression of at least one gene in Gs; (2) screening (M3)
CC for an agent capable of modulating GCA or an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease using the
CC gene expression profile; (3) detecting (M4) an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease, by detecting the
CC level of expression in a sample of the tissue of gene(s) from Gs, where
CC the level of expression of the gene is indicative of inflammation;
CC (4) treating (M5) an inflammation (especially chronic) or in a tissue,
CC an allergic response in a subject, exposure of a subject to a pathogen
CC or sterile inflammatory disease, by contacting a tissue having
CC inflammation with an agent that modulates the expression of gene(s)
CC from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC modulating GA; M3 is useful for screening an agent capable of modulating
CC GCA preferably in an inflammation in a tissue; M4 is useful for
CC detecting an inflammation (especially chronic) in a tissue, an allergic
CC response in a subject, exposure of a subject to a pathogen or sterile
CC inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
CC reperfusion injury, ARDS, adult respiratory distress syndrome,
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC periodontal disease; also bacterial infection, viral infection,
CC parasitic infection, protozoal infection, fungal infection and M5 is
CC useful for treating one of the above conditions. The present
CC sequence represents a gene differentially expressed in granulocytes.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 112460 BP; 24087 A; 29523 C; 31203 G; 27647 T; 0 other;

Query Match 2.5%; Score 64; DB 24; Length 112460;
Best Local Similarity 100.0%; Pred. No. 6.3e-15;
Matches 64; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2053 AACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTG 2112
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 110459 AACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTG 110518

Qy 2113 TGAG 2116
||||
Db 110519 TGAG 110522

RESULT 46
AAK77173
ID AAK77173 standard; DNA; 23394 BP.
XX
AC AAK77173;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:31985.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.

XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX

DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure; SEQ ID NO 31985; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 23394 BP; 6799 A; 4034 C; 4599 G; 7962 T; 0 other;

Query Match 2.5%; Score 63; DB 22; Length 23394;
Best Local Similarity 100.0%; Pred. No. 1.9e-14;
Matches 63; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2058 CTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGC 2117
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4821 CTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGC 4880

Qy 2118 CAC 2120
|||
Db 4881 CAC 4883

RESULT 47
AAL03793
ID AAL03793 standard; DNA; 405 BP.
XX
AC AAL03793;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human reproductive system related antigen DNA SEQ ID NO: 6481.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200155320-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01339.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.

PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 6481; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 405 BP; 101 A; 106 C; 88 G; 110 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 405;
Best Local Similarity 100.0%; Pred. No. 2.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 77 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 136

Qy 2110 G 2110
|
Db 137 G 137

RESULT 48
AAI62607
ID AAI62607 standard; DNA; 405 BP.
XX
AC AAI62607;
XX
DT 19-OCT-2001 (first entry)
XX
DE Human breast or ovarian antigen genomic DNA SEQ ID NO: 257.
XX
KW Human; breast antigen; ovarian antigen; cancer; metastasis; gene therapy;
KW ds.
XX
OS Homo sapiens.
XX
PN WO200155324-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01344.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.

PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488785/53.
XX
PT New isolated nucleic acids and polypeptides, useful for diagnosing,
PT treating and/or preventing human diseases and disorders -
XX
PS Disclosure; SEQ ID NO: 257; 520pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of ovarian and breast antigens. These are shown in
CC AAI62467-AAI62572 and AAM42240-AAM42345. The sequences can be used in the
CC diagnosis, prevention and treatment of breast and ovarian cancers, and
CC their metastases. The present sequence is a genomic sequence of the
CC invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 405 BP; 101 A; 106 C; 88 G; 110 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 405;
Best Local Similarity 100.0%; Pred. No. 2.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 77 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 136

Qy 2110 G 2110
|
Db 137 G 137

RESULT 49
ABK72132
ID ABK72132 standard; DNA; 405 BP.
XX
AC ABK72132;
XX
DT 13-AUG-2002 (first entry)
XX
DE Human ovarian antigen #47 genomic sequence #2.
XX
KW Human; ds; ovarian antigen; ovary disorder; breast disorder;
KW neoplastic disorder; cancer; infectious disease; inflammatory disease;
KW reproductive system disorder; autoimmune disorder; Alzheimer's disease;

KW blood-related disorder; hyperproliferative disorder; hair loss;
KW urinary system disorder; cardiovascular disorder; arrhythmia;
KW respiratory disorder; musculoskeletal system disorder;
KW neural activity disorder; neurological disorder; endocrine disorder;
KW gastrointestinal disorder; liver disorder; pancreatic disorder;
KW gall bladder disorder; large intestine disorder; developmental disorder;
KW inherited disorder; wound healing; skin aging; food additive;
KW preservative.
XX
OS Homo sapiens.
XX
PN WO200155329-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01360.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 07-JUN-2000; 2000US-0209467.
PR 14-SEP-2000; 2000US-0232398.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251990.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476195/51.
XX
PT Novel isolated human ovarian related polypeptide useful for
PT diagnosis/treatment of disorders of ovary and breast such as neoplastic
PT disorders, infectious diseases, inflammatory diseases, and reproductive
PT disorders -
XX
PS Disclosure; SEQ ID No 159; 524pp; English.
XX
CC The invention relates to isolated ovarian related polypeptide (ovarian
CC antigen) comprising a sequence at least 90% identical to a sequence
CC selected from a polypeptide fragment, domain, epitope or full length
CC protein of a sequence (S1) appearing as ABG60239-ABG60296 having
CC biological activity, or a variant, allelic variant or species homologue
CC of S1. Also included are the cDNA clones encoding the proteins of S1.
CC S1, an anti-S1 antibody and the cDNA are useful for diagnosing,
CC preventing, treating or ameliorating a medical condition in mammalian
CC subject especially diseases and/or disorders of the ovary
CC and/or breast such as neoplastic disorders (such as ovarian Krukenberg
CC tumour and cancer), infectious diseases (e.g., mastitis, oophoritis),
CC inflammatory diseases (e.g., abscesses), reproductive system disorders
CC (Paget's disease), autoimmune disorders (systemic lupus erythematosus,
CC rheumatoid arthritis), blood-related disorders (sickle cell anaemia),
CC hyperproliferative disorders, urinary system disorders
CC (glomerulonephritis), cardiovascular disorders (arrhythmias),
CC respiratory disorders, musculoskeletal system disorders, neural
CC activity and neurological disorders (Alzheimer's disease and
CC Parkinson's disease), endocrine disorders (Addison's disease),
CC gastrointestinal disorders (inflammatory disorders), liver disorders
CC (biliary liver cirrhosis), pancreatic and gall bladder disorders,
CC disorders of the large intestine, developmental and inherited
CC disorders, diseases at the cellular level, and wound healing and
CC epithelial cell proliferation. They are also useful to prevent skin
CC aging, for preventing hair loss, to maintain organs before
CC transplantation or for supporting cell culture of primary tissues, to
CC modulate mammalian characteristics such as body height, to modulate
CC mammalian metabolism, to change a mammal's mental or physical state,
CC and as food additive or preservative. The present sequence is a
CC partial genomic sequence for an S1 protein.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

XX
SQ Sequence 405 BP; 101 A; 106 C; 88 G; 110 T; 0 other;

Query Match 2.4%; Score 61; DB 23; Length 405;
Best Local Similarity 100.0%; Pred. No. 2.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 77 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 136

Qy 2110 G 2110
|
Db 137 G 137

RESULT 50
ABK91724
ID ABK91724 standard; DNA; 405 BP.
XX
AC ABK91724;
XX
DT 26-AUG-2002 (first entry)
XX
DE Novel ovarian related polynucleotide #33.
XX
KW Ovarian related polypeptide; neoplastic disorder; tumour; ovarian cancer;
KW hyperproliferative disorder; adult acute lymphocytic leukaemia;
KW breast cancer; reproductive system disorder; tuberculosis; arthritis;
KW immune system disorder; Chediak-Higashi's syndrome; neonatal neutropenia;
KW autoimmune disorder; Hashimoto's thyroiditis; inflammatory disorder;
KW septic shock; multiple sclerosis; central nervous system disorder;
KW neurological disorder; allergy; Parkinson's disease; Alzheimer's disease;
KW cardiovascular disorder; atherosclerosis; blood related disorder;
KW respiratory disorder; urinary system disorder; musculoskeletal disorder;
KW osteoporosis; wound healing; endocrine disorder; infectious disease;
KW gastrointestinal disorder; transplantation; food additive; preservative;
KW ds.
XX
OS Homo sapiens.
XX
PN US2002045230-A1.
XX
PD 18-APR-2002.
XX
PF 20-JUL-2001; 2001US-0908711.
XX
PR 31-JAN-2000; 2000US-179065P.
PR 04-FEB-2000; 2000US-180628P.
PR 24-FEB-2000; 2000US-184664P.
PR 02-MAR-2000; 2000US-186350P.
PR 16-MAR-2000; 2000US-189874P.
PR 17-MAR-2000; 2000US-190076P.
PR 18-APR-2000; 2000US-198123P.
PR 19-MAY-2000; 2000US-205515P.
PR 07-JUN-2000; 2000US-209467P.
PR 28-JUN-2000; 2000US-214886P.
PR 30-JUN-2000; 2000US-215135P.
PR 07-JUL-2000; 2000US-216647P.
PR 07-JUL-2000; 2000US-216880P.
PR 11-JUL-2000; 2000US-217487P.
PR 11-JUL-2000; 2000US-217496P.
PR 14-JUL-2000; 2000US-218290P.
PR 26-JUL-2000; 2000US-220963P.
PR 26-JUL-2000; 2000US-220964P.
PR 14-AUG-2000; 2000US-224518P.
PR 14-AUG-2000; 2000US-224519P.
PR 14-AUG-2000; 2000US-225213P.
PR 14-AUG-2000; 2000US-225214P.
PR 14-AUG-2000; 2000US-225266P.
PR 14-AUG-2000; 2000US-225267P.
PR 14-AUG-2000; 2000US-225268P.
PR 14-AUG-2000; 2000US-225270P.

PR 14-AUG-2000; 2000US-225447P.
PR 14-AUG-2000; 2000US-225757P.
PR 14-AUG-2000; 2000US-225758P.
PR 14-AUG-2000; 2000US-225759P.
PR 18-AUG-2000; 2000US-226279P.
PR 22-AUG-2000; 2000US-226681P.
PR 22-AUG-2000; 2000US-226868P.
PR 22-AUG-2000; 2000US-227182P.
PR 23-AUG-2000; 2000US-227009P.
PR 30-AUG-2000; 2000US-228924P.
PR 01-SEP-2000; 2000US-229287P.
PR 01-SEP-2000; 2000US-229343P.
PR 01-SEP-2000; 2000US-229344P.
PR 01-SEP-2000; 2000US-229345P.
PR 05-SEP-2000; 2000US-229509P.
PR 05-SEP-2000; 2000US-229513P.
PR 06-SEP-2000; 2000US-230437P.
PR 06-SEP-2000; 2000US-230438P.
PR 08-SEP-2000; 2000US-231242P.
PR 08-SEP-2000; 2000US-231243P.
PR 08-SEP-2000; 2000US-231244P.
PR 08-SEP-2000; 2000US-231413P.
PR 08-SEP-2000; 2000US-231414P.
PR 08-SEP-2000; 2000US-232080P.
PR 08-SEP-2000; 2000US-232081P.
PR 12-SEP-2000; 2000US-231968P.
PR 14-SEP-2000; 2000US-232397P.
PR 14-SEP-2000; 2000US-232398P.
PR 14-SEP-2000; 2000US-232399P.
PR 14-SEP-2000; 2000US-232400P.
PR 14-SEP-2000; 2000US-232401P.
PR 14-SEP-2000; 2000US-233063P.
PR 14-SEP-2000; 2000US-233064P.
PR 14-SEP-2000; 2000US-233065P.
PR 21-SEP-2000; 2000US-234223P.
PR 21-SEP-2000; 2000US-234274P.
PR 25-SEP-2000; 2000US-234997P.
PR 25-SEP-2000; 2000US-234998P.
PR 26-SEP-2000; 2000US-235484P.
PR 27-SEP-2000; 2000US-235834P.
PR 27-SEP-2000; 2000US-235836P.
PR 29-SEP-2000; 2000US-236327P.
PR 29-SEP-2000; 2000US-236367P.
PR 29-SEP-2000; 2000US-236368P.
PR 29-SEP-2000; 2000US-236369P.
PR 29-SEP-2000; 2000US-236370P.
PR 02-OCT-2000; 2000US-236802P.
PR 02-OCT-2000; 2000US-237037P.
PR 02-OCT-2000; 2000US-237038P.
PR 02-OCT-2000; 2000US-237039P.
PR 02-OCT-2000; 2000US-237040P.
PR 13-OCT-2000; 2000US-239935P.
PR 13-OCT-2000; 2000US-239937P.
PR 20-OCT-2000; 2000US-240960P.
PR 20-OCT-2000; 2000US-241221P.
PR 20-OCT-2000; 2000US-241785P.
PR 20-OCT-2000; 2000US-241786P.
PR 20-OCT-2000; 2000US-241787P.
PR 20-OCT-2000; 2000US-241808P.
PR 20-OCT-2000; 2000US-241809P.
PR 20-OCT-2000; 2000US-241826P.
PR 01-NOV-2000; 2000US-244617P.
PR 08-NOV-2000; 2000US-246474P.
PR 08-NOV-2000; 2000US-246475P.
PR 08-NOV-2000; 2000US-246476P.
PR 08-NOV-2000; 2000US-246477P.
PR 08-NOV-2000; 2000US-246478P.
PR 08-NOV-2000; 2000US-246523P.
PR 08-NOV-2000; 2000US-246524P.
PR 08-NOV-2000; 2000US-246525P.
PR 08-NOV-2000; 2000US-246526P.
PR 08-NOV-2000; 2000US-246527P.
PR 08-NOV-2000; 2000US-246528P.
PR 08-NOV-2000; 2000US-246532P.
PR 08-NOV-2000; 2000US-246609P.
PR 08-NOV-2000; 2000US-246610P.
PR 08-NOV-2000; 2000US-246611P.
PR 08-NOV-2000; 2000US-246613P.
PR 17-NOV-2000; 2000US-249207P.
PR 17-NOV-2000; 2000US-249208P.
PR 17-NOV-2000; 2000US-249209P.
PR 17-NOV-2000; 2000US-249210P.
PR 17-NOV-2000; 2000US-249211P.
PR 17-NOV-2000; 2000US-249212P.
PR 17-NOV-2000; 2000US-249213P.
PR 17-NOV-2000; 2000US-249214P.
PR 17-NOV-2000; 2000US-249215P.
PR 17-NOV-2000; 2000US-249216P.
PR 17-NOV-2000; 2000US-249217P.
PR 17-NOV-2000; 2000US-249218P.
PR 17-NOV-2000; 2000US-249244P.
PR 17-NOV-2000; 2000US-249245P.
PR 17-NOV-2000; 2000US-249264P.
PR 17-NOV-2000; 2000US-249265P.
PR 17-NOV-2000; 2000US-249297P.
PR 17-NOV-2000; 2000US-249299P.
PR 17-NOV-2000; 2000US-249300P.
PR 01-DEC-2000; 2000US-250160P.
PR 01-DEC-2000; 2000US-250391P.
PR 05-DEC-2000; 2000US-251030P.
PR 05-DEC-2000; 2000US-251988P.
PR 05-DEC-2000; 2000US-256719P.
PR 06-DEC-2000; 2000US-251479P.
PR 08-DEC-2000; 2000US-251856P.
PR 08-DEC-2000; 2000US-251868P.
PR 08-DEC-2000; 2000US-251869P.
PR 08-DEC-2000; 2000US-251989P.
PR 08-DEC-2000; 2000US-251990P.
PR 11-DEC-2000; 2000US-254097P.
PR 05-JAN-2001; 2001US-259678P.
PR 17-JAN-2001; 2001US-0764853.
PR 17-JAN-2001; 2001US-0764856.
PR 17-JAN-2001; 2001US-0764864.
PR 17-JAN-2001; 2001US-0764867.
PR 17-JAN-2001; 2001US-0764868.
PR 17-JAN-2001; 2001US-0764869.
PR 17-JAN-2001; 2001US-0764870.
PR 17-JAN-2001; 2001US-0764874.
PR 17-JAN-2001; 2001US-0764882.
PR 17-JAN-2001; 2001US-0764888.
PR 17-JAN-2001; 2001US-0764891.
PR 17-JAN-2001; 2001US-0764892.
PR 17-JAN-2001; 2001US-0764896.
PR 17-JAN-2001; 2001US-0764898.
PR 17-JAN-2001; 2001US-0764902.
PR 17-JAN-2001; 2001US-0764905.
PR 17-JAN-2001; 2001WO-US01239.
PR 17-JAN-2001; 2001WO-US01307.
PR 17-JAN-2001; 2001WO-US01312.
PR 17-JAN-2001; 2001WO-US01320.
PR 17-JAN-2001; 2001WO-US01329.
PR 17-JAN-2001; 2001WO-US01334.
PR 17-JAN-2001; 2001WO-US01336.
PR 17-JAN-2001; 2001WO-US01339.
PR 17-JAN-2001; 2001WO-US01340.
PR 17-JAN-2001; 2001WO-US01341.
PR 17-JAN-2001; 2001WO-US01344.
PR 17-JAN-2001; 2001WO-US01345.
PR 17-JAN-2001; 2001WO-US01347.
PR 17-JAN-2001; 2001WO-US01348.
PR 17-JAN-2001; 2001WO-US01360.
XX
PA (ROSE/) ROSEN C A.
PA (RUBI/) RUBIN S M.
PA (BARA/) BARASH S C.

```
  Query Match             2.4%;  Score 61;  DB 24;  Length 405;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-13;
  Matches   61;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy   2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     77 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 136

Qy   2110 G 2110
          |
Db    137 G 137


RESULT 51
AAL00601
ID   AAL00601 standard; cDNA; 418 BP.
XX
AC   AAL00601;
XX
DT   21-NOV-2001  (first entry)
XX
DE   Human reproductive system related antigen cDNA SEQ ID NO: 602.
XX
KW   Human; reproductive system related antigen; reproductive system disorder;
KW   cancer; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200155320-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01339.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
```

PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
DR P-PSDB; AAM94631.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Claim 1; SEQ ID NO 602; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a coding sequence of the
CC invention.
XX
SQ Sequence 418 BP; 102 A; 110 C; 96 G; 105 T; 5 other;

Query Match 2.4%; Score 61; DB 22; Length 418;
Best Local Similarity 100.0%; Pred. No. 2.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 96 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 155

Qy 2110 G 2110
|
Db 156 G 156

RESULT 52
AAI62488
ID AAI62488 standard; cDNA; 418 BP.
XX
AC AAI62488;
XX
DT 19-OCT-2001 (first entry)
XX
DE Human breast or ovarian antigen coding sequence SEQ ID NO: 32.
XX
KW Human; breast antigen; ovarian antigen; cancer; metastasis; gene therapy;
KW ss.
XX
OS Homo sapiens.
XX

PN WO200155324-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01344.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.

PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488785/53.
DR P-PSDB; AAM42261.
XX
PT New isolated nucleic acids and polypeptides, useful for diagnosing,
PT treating and/or preventing human diseases and disorders -
XX
PS Claim 1; SEQ ID NO: 32; 520pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of ovarian and breast antigens. These are shown in
CC AAI62467-AAI62572 and AAM42240-AAM42345. The sequences can be used in the
CC diagnosis, prevention and treatment of breast and ovarian cancers, and
CC their metastases. The present sequence is a coding sequence of the
CC invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 418 BP; 102 A; 110 C; 96 G; 105 T; 5 other;

Query Match 2.4%; Score 61; DB 22; Length 418;
Best Local Similarity 100.0%; Pred. No. 2.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 96 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 155

Qy 2110 G 2110
|
Db 156 G 156

RESULT 53
ABK72088
ID ABK72088 standard; cDNA; 418 BP.
XX
AC ABK72088;
XX
DT 13-AUG-2002 (first entry)
XX
DE Human cDNA encoding ovarian antigen #47.
XX
KW Human; ss; ovarian antigen; gene; ovary disorder; breast disorder;
KW neoplastic disorder; cancer; infectious disease; inflammatory disease;
KW reproductive system disorder; autoimmune disorder; Alzheimer's disease;
KW blood-related disorder; hyperproliferative disorder; hair loss;
KW urinary system disorder; cardiovascular disorder; arrhythmia;
KW respiratory disorder; musculoskeletal system disorder;
KW neural activity disorder; neurological disorder; endocrine disorder;
KW gastrointestinal disorder; liver disorder; pancreatic disorder;
KW gall bladder disorder; large intestine disorder; developmental disorder;
KW inherited disorder; wound healing; skin aging; food additive;
KW preservative.
XX
OS Homo sapiens.
XX
PN WO200155329-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01360.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 07-JUN-2000; 2000US-0209467.
PR 14-SEP-2000; 2000US-0232398.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251990.
XX

PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476195/51.
DR P-PSDB; ABG60285.
XX
PT Novel isolated human ovarian related polypeptide useful for
PT diagnosis/treatment of disorders of ovary and breast such as neoplastic
PT disorders, infectious diseases, inflammatory diseases, and reproductive
PT disorders -
XX
PS Claim 1; SEQ ID No 57; 524pp; English.
XX
CC The invention relates to isolated ovarian related polypeptide (ovarian
CC antigen) comprising a sequence at least 90% identical to a sequence
CC selected from a polypeptide fragment, domain, epitope or full length
CC protein of a sequence (S1) appearing as ABG60239-ABG60296 having
CC biological activity, or a variant, allelic variant or species homologue
CC of S1. Also included are the cDNA clones encoding the proteins of S1.
CC S1, an anti-S1 antibody and the cDNA are useful for diagnosing,
CC preventing, treating or ameliorating a medical condition in mammalian
CC subject especially diseases and/or disorders of the ovary
CC and/or breast such as neoplastic disorders (such as ovarian Krukenberg
CC tumour and cancer), infectious diseases (e.g., mastitis, oophoritis),
CC inflammatory diseases (e.g., abscesses), reproductive system disorders
CC (Paget's disease), autoimmune disorders (systemic lupus erythematosus,
CC rheumatoid arthritis), blood-related disorders (sickle cell anaemia),
CC hyperproliferative disorders, urinary system disorders
CC (glomerulonephritis), cardiovascular disorders (arrhythmias),
CC respiratory disorders, musculoskeletal system disorders, neural
CC activity and neurological disorders (Alzheimer's disease and
CC Parkinson's disease), endocrine disorders (Addison's disease),
CC gastrointestinal disorders (inflammatory disorders), liver disorders
CC (biliary liver cirrhosis), pancreatic and gall bladder disorders,
CC disorders of the large intestine, developmental and inherited
CC disorders, diseases at the cellular level, and wound healing and
CC epithelial cell proliferation. They are also useful to prevent skin
CC aging, for preventing hair loss, to maintain organs before
CC transplantation or for supporting cell culture of primary tissues, to
CC modulate mammalian characteristics such as body height, to modulate
CC mammalian metabolism, to change a mammal's mental or physical state,
CC and as food additive or preservative. The present sequence is a
CC cDNA encoding an S1 protein.
XX
SQ Sequence 418 BP; 102 A; 110 C; 96 G; 105 T; 5 other;

Query Match 2.4%; Score 61; DB 23; Length 418;
Best Local Similarity 100.0%; Pred. No. 2.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 96 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 155

Qy 2110 G 2110
|
Db 156 G 156

RESULT 54
ABK91680
ID ABK91680 standard; cDNA; 418 BP.
XX
AC ABK91680;
XX
DT 26-AUG-2002 (first entry)
XX
DE cDNA encoding novel ovarian related polypeptide #47.
XX
KW Ovarian related polypeptide; neoplastic disorder; tumour; ovarian cancer;
KW hyperproliferative disorder; adult acute lymphocytic leukaemia;
KW breast cancer; reproductive system disorder; tuberculosis; arthritis;
KW immune system disorder; Chediak-Higashi's syndrome; neonatal neutropenia;
KW autoimmune disorder; Hashimoto's thyroiditis; inflammatory disorder;
KW septic shock; multiple sclerosis; central nervous system disorder;
KW neurological disorder; allergy; Parkinson's disease; Alzheimer's disease;
KW cardiovascular disorder; atherosclerosis; blood related disorder;
KW respiratory disorder; urinary system disorder; musculoskeletal disorder;
KW osteoporosis; wound healing; endocrine disorder; infectious disease;
KW gastrointestinal disorder; transplantation; food additive; preservative;
KW gene; ss.
XX
OS Homo sapiens.
XX
PN US2002045230-A1.
XX
PD 18-APR-2002.
XX
PF 20-JUL-2001; 2001US-0908711.
XX
PR 31-JAN-2000; 2000US-179065P.
PR 04-FEB-2000; 2000US-180628P.
PR 24-FEB-2000; 2000US-184664P.
PR 02-MAR-2000; 2000US-186350P.
PR 16-MAR-2000; 2000US-189874P.
PR 17-MAR-2000; 2000US-190076P.
PR 18-APR-2000; 2000US-198123P.
PR 19-MAY-2000; 2000US-205515P.
PR 07-JUN-2000; 2000US-209467P.
PR 28-JUN-2000; 2000US-214886P.
PR 30-JUN-2000; 2000US-215135P.
PR 07-JUL-2000; 2000US-216647P.
PR 07-JUL-2000; 2000US-216880P.
PR 11-JUL-2000; 2000US-217487P.
PR 11-JUL-2000; 2000US-217496P.
PR 14-JUL-2000; 2000US-218290P.
PR 26-JUL-2000; 2000US-220963P.
PR 26-JUL-2000; 2000US-220964P.
PR 14-AUG-2000; 2000US-224518P.
PR 14-AUG-2000; 2000US-224519P.
PR 14-AUG-2000; 2000US-225213P.
PR 14-AUG-2000; 2000US-225214P.
PR 14-AUG-2000; 2000US-225266P.
PR 14-AUG-2000; 2000US-225267P.
PR 14-AUG-2000; 2000US-225268P.
PR 14-AUG-2000; 2000US-225270P.
PR 14-AUG-2000; 2000US-225447P.
PR 14-AUG-2000; 2000US-225757P.
PR 14-AUG-2000; 2000US-225758P.
PR 14-AUG-2000; 2000US-225759P.
PR 18-AUG-2000; 2000US-226279P.
PR 22-AUG-2000; 2000US-226681P.
PR 22-AUG-2000; 2000US-226868P.
PR 22-AUG-2000; 2000US-227182P.
PR 23-AUG-2000; 2000US-227009P.
PR 30-AUG-2000; 2000US-228924P.
PR 01-SEP-2000; 2000US-229287P.
PR 01-SEP-2000; 2000US-229343P.
PR 01-SEP-2000; 2000US-229344P.
PR 01-SEP-2000; 2000US-229345P.
PR 05-SEP-2000; 2000US-229509P.
PR 05-SEP-2000; 2000US-229513P.
PR 06-SEP-2000; 2000US-230437P.
PR 06-SEP-2000; 2000US-230438P.
PR 08-SEP-2000; 2000US-231242P.
PR 08-SEP-2000; 2000US-231243P.
PR 08-SEP-2000; 2000US-231244P.
PR 08-SEP-2000; 2000US-231413P.
PR 08-SEP-2000; 2000US-231414P.
PR 08-SEP-2000; 2000US-232080P.
PR 08-SEP-2000; 2000US-232081P.
PR 12-SEP-2000; 2000US-231968P.
PR 14-SEP-2000; 2000US-232397P.
PR 14-SEP-2000; 2000US-232398P.
PR 14-SEP-2000; 2000US-232399P.

PR 14-SEP-2000; 2000US-232400P.
PR 14-SEP-2000; 2000US-232401P.
PR 14-SEP-2000; 2000US-233063P.
PR 14-SEP-2000; 2000US-233064P.
PR 14-SEP-2000; 2000US-233065P.
PR 21-SEP-2000; 2000US-234223P.
PR 21-SEP-2000; 2000US-234274P.
PR 25-SEP-2000; 2000US-234997P.
PR 25-SEP-2000; 2000US-234998P.
PR 26-SEP-2000; 2000US-235484P.
PR 27-SEP-2000; 2000US-235834P.
PR 27-SEP-2000; 2000US-235836P.
PR 29-SEP-2000; 2000US-236327P.
PR 29-SEP-2000; 2000US-236367P.
PR 29-SEP-2000; 2000US-236368P.
PR 29-SEP-2000; 2000US-236369P.
PR 29-SEP-2000; 2000US-236370P.
PR 02-OCT-2000; 2000US-236802P.
PR 02-OCT-2000; 2000US-237037P.
PR 02-OCT-2000; 2000US-237038P.
PR 02-OCT-2000; 2000US-237039P.
PR 02-OCT-2000; 2000US-237040P.
PR 13-OCT-2000; 2000US-239935P.
PR 13-OCT-2000; 2000US-239937P.
PR 20-OCT-2000; 2000US-240960P.
PR 20-OCT-2000; 2000US-241221P.
PR 20-OCT-2000; 2000US-241785P.
PR 20-OCT-2000; 2000US-241786P.
PR 20-OCT-2000; 2000US-241787P.
PR 20-OCT-2000; 2000US-241808P.
PR 20-OCT-2000; 2000US-241809P.
PR 20-OCT-2000; 2000US-241826P.
PR 01-NOV-2000; 2000US-244617P.
PR 08-NOV-2000; 2000US-246474P.
PR 08-NOV-2000; 2000US-246475P.
PR 08-NOV-2000; 2000US-246476P.
PR 08-NOV-2000; 2000US-246477P.
PR 08-NOV-2000; 2000US-246478P.
PR 08-NOV-2000; 2000US-246523P.
PR 08-NOV-2000; 2000US-246524P.
PR 08-NOV-2000; 2000US-246525P.
PR 08-NOV-2000; 2000US-246526P.
PR 08-NOV-2000; 2000US-246527P.
PR 08-NOV-2000; 2000US-246528P.
PR 08-NOV-2000; 2000US-246532P.
PR 08-NOV-2000; 2000US-246609P.
PR 08-NOV-2000; 2000US-246610P.
PR 08-NOV-2000; 2000US-246611P.
PR 08-NOV-2000; 2000US-246613P.
PR 17-NOV-2000; 2000US-249207P.
PR 17-NOV-2000; 2000US-249208P.
PR 17-NOV-2000; 2000US-249209P.
PR 17-NOV-2000; 2000US-249210P.
PR 17-NOV-2000; 2000US-249211P.
PR 17-NOV-2000; 2000US-249212P.
PR 17-NOV-2000; 2000US-249213P.
PR 17-NOV-2000; 2000US-249214P.
PR 17-NOV-2000; 2000US-249215P.
PR 17-NOV-2000; 2000US-249216P.
PR 17-NOV-2000; 2000US-249217P.
PR 17-NOV-2000; 2000US-249218P.
PR 17-NOV-2000; 2000US-249244P.
PR 17-NOV-2000; 2000US-249245P.
PR 17-NOV-2000; 2000US-249264P.
PR 17-NOV-2000; 2000US-249265P.
PR 17-NOV-2000; 2000US-249297P.
PR 17-NOV-2000; 2000US-249299P.
PR 17-NOV-2000; 2000US-249300P.
PR 01-DEC-2000; 2000US-250160P.
PR 01-DEC-2000; 2000US-250391P.
PR 05-DEC-2000; 2000US-251030P.
PR 05-DEC-2000; 2000US-251988P.
PR 05-DEC-2000; 2000US-256719P.
PR 06-DEC-2000; 2000US-251479P.
PR 08-DEC-2000; 2000US-251856P.
PR 08-DEC-2000; 2000US-251868P.
PR 08-DEC-2000; 2000US-251869P.
PR 08-DEC-2000; 2000US-251989P.
PR 08-DEC-2000; 2000US-251990P.
PR 11-DEC-2000; 2000US-254097P.
PR 05-JAN-2001; 2001US-259678P.
PR 17-JAN-2001; 2001US-0764853.
PR 17-JAN-2001; 2001US-0764856.
PR 17-JAN-2001; 2001US-0764864.
PR 17-JAN-2001; 2001US-0764867.
PR 17-JAN-2001; 2001US-0764868.
PR 17-JAN-2001; 2001US-0764869.
PR 17-JAN-2001; 2001US-0764870.
PR 17-JAN-2001; 2001US-0764874.
PR 17-JAN-2001; 2001US-0764882.
PR 17-JAN-2001; 2001US-0764888.
PR 17-JAN-2001; 2001US-0764891.
PR 17-JAN-2001; 2001US-0764892.
PR 17-JAN-2001; 2001US-0764896.
PR 17-JAN-2001; 2001US-0764898.
PR 17-JAN-2001; 2001US-0764902.
PR 17-JAN-2001; 2001US-0764905.
PR 17-JAN-2001; 2001WO-US01239.
PR 17-JAN-2001; 2001WO-US01307.
PR 17-JAN-2001; 2001WO-US01312.
PR 17-JAN-2001; 2001WO-US01320.
PR 17-JAN-2001; 2001WO-US01329.
PR 17-JAN-2001; 2001WO-US01334.
PR 17-JAN-2001; 2001WO-US01336.
PR 17-JAN-2001; 2001WO-US01339.
PR 17-JAN-2001; 2001WO-US01340.
PR 17-JAN-2001; 2001WO-US01341.
PR 17-JAN-2001; 2001WO-US01344.
PR 17-JAN-2001; 2001WO-US01345.
PR 17-JAN-2001; 2001WO-US01347.
PR 17-JAN-2001; 2001WO-US01348.
PR 17-JAN-2001; 2001WO-US01360.
XX
PA (ROSE/) ROSEN C A.
PA (RUBI/) RUBIN S M.
PA (BARA/) BARASH S C.

Query Match 2.4%; Score 61; DB 24; Length 418;
Best Local Similarity 100.0%; Pred. No. 2.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 96 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 155

Qy 2110 G 2110
|
Db 156 G 156

RESULT 55
ABV50873
ID ABV50873 standard; cDNA; 458 BP.
XX
AC ABV50873;
XX
DT 17-SEP-2002 (first entry)
XX
DE Human prostate expression marker cDNA 50864.
XX
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodyanamic marker;
KW pharmacogenomic marker; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200160860-A2.

XX
PD 23-AUG-2001.
XX
PF 20-FEB-2001; 2001WO-US05171.
XX
PR 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Schlegel R, Endege WO, Monahan JE;
XX
DR WPI; 2001-662795/76.
XX
PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer -
XX
PS Claim 1; Page 9893; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (I) is also useful as a pharmacodyanamic or pharmacogenomic marker.
XX
SQ Sequence 458 BP; 120 A; 121 C; 88 G; 128 T; 1 other;

Query Match 2.4%; Score 61; DB 23; Length 458;
Best Local Similarity 100.0%; Pred. No. 2.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 174 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 233

Qy 2110 G 2110
|
Db 234 G 234

RESULT 56
AAH15514/c
ID AAH15514 standard; cDNA; 2007 BP.
XX
AC AAH15514;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human cDNA sequence SEQ ID NO:13778.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-0116126.
XX
PR 29-JUL-1999; 99JP-0248036.
PR 27-AUG-1999; 99JP-0300253.
PR 11-JAN-2000; 2000JP-0118776.
PR 02-MAY-2000; 2000JP-0183767.
PR 09-JUN-2000; 2000JP-0241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI; 2001-318749/34.
XX
PT Primer sets for synthesizing polynucleotides, particularly the 5602
PT full-length cDNAs defined in the specification, and for the detection
PT and/or diagnosis of the abnormality of the proteins encoded by the
PT full-length cDNAs -
XX
PS Claim 8; SEQ ID 13778; 2537pp + CD ROM; English.
XX
CC The present invention describes primer sets for synthesising 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesising polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.
XX
SQ Sequence 2007 BP; 668 A; 351 C; 441 G; 547 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 2007;
Best Local Similarity 100.0%; Pred. No. 1.6e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2060 GACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCA 2119
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 712 GACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCA 653

Qy 2120 C 2120
|
Db 652 C 652

RESULT 57
AAS28641/c
ID AAS28641 standard; DNA; 6186 BP.
XX
AC AAS28641;
XX
DT 07-NOV-2001 (first entry)
XX
DE Genomic sequence #481 encoding for novel human respiratory antigen.
XX
KW Human; respiratory antigen; respiratory disorder; throat disorder;
KW lung disorder; nose disorder; lung cancer; gene therapy; cytostatic;
KW anti allergic; anti asthmatic; anti inflammatory; olfactory;

KW respiratory active; ds.
XX
OS Homo sapiens.
XX
PN WO200155448-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01333.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.

XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476224/51.
XX
PT Isolated polypeptide for treating, preventing and/ or prognosing
PT disorders related to the respiratory system including respiratory
PT cancers and also for testing and detection e.g. diagnosis -
XX
PS Disclosure; SED ID No 1075; 546pp; English.
XX
CC The present invention relates to the isolation of novel human
CC respiratory antigens (AAU17685-AAU17975), and cDNA and genomic
CC sequences encoding for these polypeptides. The sequences of the
CC invention are useful for preventing, treating and/or prognosing
CC disorders related to the respiratory system including throat
CC disorders (e.g. vocal cord paralysis, tonsillitis, and laryngitis),
CC lung disorders e.g. pneumonia, allergic disorders e.g. asthma,
CC pleurisy, cystic fibrosis, emphysema, nose disorders and cancers of
CC the respiratory tissues e.g. lung cancer. The polynucleotide sequences
CC of the invention are useful in gene therapy and antisense therapy.
CC AAS28161-AAS28764 represent genomic sequences encoding for novel
CC human respiratory antigens.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 6186 BP; 1716 A; 1376 C; 1485 G; 1609 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 6186;
Best Local Similarity 100.0%; Pred. No. 1.4e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 5321 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 5262

Qy 2110 G 2110
|
Db 5261 G 5261

RESULT 58
AAS28642/c
ID AAS28642 standard; DNA; 6191 BP.
XX
AC AAS28642;
XX
DT 07-NOV-2001 (first entry)
XX
DE Genomic sequence #482 encoding for novel human respiratory antigen.
XX
KW Human; respiratory antigen; respiratory disorder; throat disorder;
KW lung disorder; nose disorder; lung cancer; gene therapy; cytostatic;
KW anti allergic; anti asthmatic; anti inflammatory; olfactory;
KW respiratory active; ds.
XX
OS Homo sapiens.
XX
PN WO200155448-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01333.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.

PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476224/51.
XX
PT Isolated polypeptide for treating, preventing and/ or prognosing
PT disorders related to the respiratory system including respiratory
PT cancers and also for testing and detection e.g. diagnosis -
XX
PS Disclosure; SED ID No 1076; 546pp; English.
XX
CC The present invention relates to the isolation of novel human
CC respiratory antigens (AAU17685-AAU17975), and cDNA and genomic
CC sequences encoding for these polypeptides. The sequences of the
CC invention are useful for preventing, treating and/or prognosing
CC disorders related to the respiratory system including throat
CC disorders (e.g. vocal cord paralysis, tonsillitis, and laryngitis),
CC lung disorders e.g. pneumonia, allergic disorders e.g. asthma,
CC pleurisy, cystic fibrosis, emphysema, nose disorders and cancers of
CC the respiratory tissues e.g. lung cancer. The polynucleotide sequences
CC of the invention are useful in gene therapy and antisense therapy.
CC AAS28161-AAS28764 represent genomic sequences encoding for novel
CC human respiratory antigens.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 6191 BP; 1719 A; 1378 C; 1484 G; 1610 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 6191;
Best Local Similarity 100.0%; Pred. No. 1.4e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 5326 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 5267

Qy 2110 G 2110
|
Db 5266 G 5266

RESULT 59
AAS28643/c
ID AAS28643 standard; DNA; 6191 BP.
XX
AC AAS28643;
XX
DT 07-NOV-2001 (first entry)
XX
DE Genomic sequence #483 encoding for novel human respiratory antigen.
XX
KW Human; respiratory antigen; respiratory disorder; throat disorder;
KW lung disorder; nose disorder; lung cancer; gene therapy; cytostatic;
KW anti allergic; anti asthmatic; anti inflammatory; olfactory;
KW respiratory active; ds.
XX
OS Homo sapiens.
XX
PN WO200155448-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01333.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.

PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476224/51.
XX
PT Isolated polypeptide for treating, preventing and/ or prognosing
PT disorders related to the respiratory system including respiratory
PT cancers and also for testing and detection e.g. diagnosis -
XX
PS Disclosure; SED ID No 1077; 546pp; English.
XX
CC The present invention relates to the isolation of novel human
CC respiratory antigens (AAU17685-AAU17975), and cDNA and genomic
CC sequences encoding for these polypeptides. The sequences of the
CC invention are useful for preventing, treating and/or prognosing
CC disorders related to the respiratory system including throat
CC disorders (e.g. vocal cord paralysis, tonsillitis, and laryngitis),
CC lung disorders e.g. pneumonia, allergic disorders e.g. asthma,
CC pleurisy, cystic fibrosis, emphysema, nose disorders and cancers of
CC the respiratory tissues e.g. lung cancer. The polynucleotide sequences
CC of the invention are useful in gene therapy and antisense therapy.
CC AAS28161-AAS28764 represent genomic sequences encoding for novel
CC human respiratory antigens.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 6191 BP; 1718 A; 1377 C; 1485 G; 1611 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 6191;

```
  Best Local Similarity   100.0%;  Pred. No. 1.4e-13;
  Matches   61;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    5326 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 5267

Qy    2110 G 2110
           |
Db    5266 G 5266


RESULT 60
ABK42222
ID   ABK42222 standard; DNA; 6191 BP.
XX
AC   ABK42222;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Genomic sequence #121 encoding novel human connective tissue polypeptide.
XX
KW   Human; connective tissue related disorder; cancer; gene therapy;
KW   cytostatic; gene; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155343-A1.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01322.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
```

PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-565190/63.
XX
PT Nucleic acid encoding novel connective tissue associated polypeptides,
PT used in diagnosing, preventing, treating or ameliorating a disorder
PT such as cancer or rheumatoid arthritis -
XX
PS Disclosure; SEQ ID No 1109; 673pp; English.
XX
CC The present invention relates to the isolation of novel human connective
CC tissue related polypeptides (AAU86435-AAU86923) and the polynucleotide
CC (cDNA and genomic) sequences encoding them. The sequences of the
CC invention are useful in the diagnosis, treatment, prevention and/or
CC prognosis of diseases associated with connective tissue(s), including
CC cancer. The polynucleotide sequences of the invention are also useful
CC in gene therapy. ABK42102-ABK43116 represent genomic sequences encoding
CC the novel human connective tissue related polypeptides.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 6191 BP; 1784 A; 1283 C; 1564 G; 1560 T; 0 other;

Query Match 2.4%; Score 61; DB 23; Length 6191;
Best Local Similarity 100.0%; Pred. No. 1.4e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3102 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 3161

Qy 2110 G 2110
|
Db 3162 G 3162

RESULT 61
ABK42223
ID ABK42223 standard; DNA; 6194 BP.
XX
AC ABK42223;
XX
DT 21-MAY-2002 (first entry)
XX
DE Genomic sequence #122 encoding novel human connective tissue polypeptide.
XX
KW Human; connective tissue related disorder; cancer; gene therapy;
KW cytostatic; gene; ds.
XX
OS Homo sapiens.
XX
PN WO200155343-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01322.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.

PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-565190/63.
XX
PT Nucleic acid encoding novel connective tissue associated polypeptides,
PT used in diagnosing, preventing, treating or ameliorating a disorder
PT such as cancer or rheumatoid arthritis -
XX
PS Disclosure; SEQ ID No 1110; 673pp; English.
XX
CC The present invention relates to the isolation of novel human connective
CC tissue related polypeptides (AAU86435-AAU86923) and the polynucleotide
CC (cDNA and genomic) sequences encoding them. The sequences of the
CC invention are useful in the diagnosis, treatment, prevention and/or
CC prognosis of diseases associated with connective tissue(s), including
CC cancer. The polynucleotide sequences of the invention are also useful
CC in gene therapy. ABK42102-ABK43116 represent genomic sequences encoding
CC the novel human connective tissue related polypeptides.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 6194 BP; 1789 A; 1281 C; 1561 G; 1563 T; 0 other;

Query Match 2.4%; Score 61; DB 23; Length 6194;
Best Local Similarity 100.0%; Pred. No. 1.4e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3106 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 3165

Qy 2110 G 2110
|
Db 3166 G 3166

RESULT 62
ABA19375
ID ABA19375 standard; DNA; 25525 BP.
XX
AC ABA19375;
XX
DT 23-JAN-2002 (first entry)
XX
DE Human nervous system related polynucleotide SEQ ID NO 11706.
XX
KW Human; nootropic; neuroprotective; cytostatic; dermatological; virucide;
KW immunosuppressive; antiinflammatory; anti-HIV; antibacterial; vulnerary;
KW antiparkinsonian; antisickling; antianaemic; antiarthritic; cancer;
KW antirheumatic; hepatotropic; cerebroprotective; antiinflammatory;
KW antiallergic; antidiabetic; antiulcer; anticonvulsant; antifungal;
KW antiparasitic; cardiant; immune disorder; cardiovascular disorder;
KW neurological disease; infection; nephrotropic; gene therapy; vaccine; ds.
XX
OS Homo sapiens.
XX
PN WO200159063-A2.
XX
PD 16-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01334.
Xx
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.

PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 20-OCT-2000; 2000US-0242221.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250391.
PR 01-DEC-2000; 2000US-0251160.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-541565/60.
XX
PT Nucleic acids encoding 3224 human nervous system antigen polypeptides,
PT useful for preventing, diagnosing and/or treating nervous system
PT cancers and metastases -
XX
PS Disclosure; SEQ ID NO 11706; 1701pp + Sequence Listing; English.
XX
CC The invention relates to novel genes (ABA11004-ABA21534) and proteins
CC (ABB14678-ABB18001) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are

CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful
CC in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
CC and ovarian cancer and other cancers of the adrenal gland, bone, bone
CC marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
CC (b) immune disorders e.g. Addison's disease, allergies, autoimmune
CC haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative
CC colitis; (c) cardiovascular disorders such as myocardial ischaemias;
CC (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
CC epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
CC and parasitic infections.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 25525 BP; 6205 A; 6343 C; 6691 G; 6286 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 25525;
Best Local Similarity 100.0%; Pred. No. 1.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2060 GACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCA 2119
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 6603 GACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCA 6662

Qy 2120 C 2120
|
Db 6663 C 6663

RESULT 63
AAK71186
ID AAK71186 standard; DNA; 26713 BP.
XX
AC AAK71186;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:25998.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.

PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure; SEQ ID NO 25998; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX

SQ Sequence 26713 BP; 8500 A; 4251 C; 5176 G; 8786 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 26713;
Best Local Similarity 100.0%; Pred. No. 1.1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 16254 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 16313

Qy 2110 G 2110
|
Db 16314 G 16314

RESULT 64
AAS30619
ID AAS30619 standard; DNA; 31994 BP.
XX
AC AAS30619;
XX
DT 21-NOV-2001 (first entry)
XX
DE DNA encoding novel lung cancer antigen, Seq ID No 71.
XX
KW Human; lung cancer; immunosuppressive; antiarthritic; antirheumatic;
KW antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
KW nootropic; neuroprotective; antibacterial; virucide; fungicide;
KW ophthalmological; autoimmune disease; rheumatoid arthritis; neoplasm;
KW hyperproliferative disorder; cardiovascular disorder; angiogenesis;
KW nervous system disorder; Alzheimer's disease; infection; skin aging;
KW ocular disorder; wound healing; organ transplantation; ds.
XX
OS Homo sapiens.
XX
PN WO200155300-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01238.
XX
PR 31-JAN-2000; 2000US-0179065.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465565/50.
XX
PT Isolated nucleic acid molecule encoding a lung cancer antigen is used
PT in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID No 71; 475pp; English.
XX
CC The invention relates to novel isolated lung cancer antigen
CC polynucleotides (I) and polypeptides (II). (I) and (II) are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. (I) and (II) are
CC also used in diagnosing a pathological condition or susceptibility to a
CC pathological condition, in particular, lung cancer. The antibodies to
CC (II) can also be used in alleviating symptoms associated with the
CC disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme
CC linked immunosorbent assays (ELISA). Disorders which are diagnosed or
CC treated include autoimmune diseases e.g. rheumatoid arthritis,
CC hyperproliferative disorders e.g. neoplasms of the breast or liver,
CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders
CC e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi and
CC ocular disorders e.g. corneal infection. The polypeptides can also be
CC used to aid wound healing and epithelial cell proliferation, to prevent
CC skin aging due to sunburn, to maintain organs before transplantation, for
CC supporting cell culture of primary tissues, to regenerate tissues and in
CC chemotaxis. AAS30580-AAS30685 represent novel human lung cancer antigen

```
CC   coding sequences, PCR primers and related sequences of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at: ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 31994 BP; 7047 A; 7778 C; 7911 G; 9258 T; 0 other;

  Query Match              2.4%;  Score 61;  DB 22;  Length 31994;
  Best Local Similarity   100.0%;  Pred. No. 1e-13;
  Matches   61;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    2060 GACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCA 2119
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    9222 GACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCA 9281

Qy    2120 C 2120
           |
Db    9282 C 9282


RESULT 65
AAS28165
ID   AAS28165 standard; DNA; 31994 BP.
XX
AC   AAS28165;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Genomic sequence #5 encoding for novel human respiratory antigen.
XX
KW   Human; respiratory antigen; respiratory disorder; throat disorder;
KW   lung disorder; nose disorder; lung cancer; gene therapy; cytostatic;
KW   anti allergic; anti asthmatic; anti inflammatory; olfactory;
KW   respiratory active; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155448-A1.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01333.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
```

PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476224/51.
XX
PT Isolated polypeptide for treating, preventing and/ or prognosing
PT disorders related to the respiratory system including respiratory
PT cancers and also for testing and detection e.g. diagnosis -
XX
PS Disclosure; SED ID No 599; 546pp; English.
XX
CC The present invention relates to the isolation of novel human
CC respiratory antigens (AAU17685-AAU17975), and cDNA and genomic
CC sequences encoding for these polypeptides. The sequences of the
CC invention are useful for preventing, treating and/or prognosing
CC disorders related to the respiratory system including throat
CC disorders (e.g. vocal cord paralysis, tonsillitis, and laryngitis),
CC lung disorders e.g. pneumonia, allergic disorders e.g. asthma,
CC pleurisy, cystic fibrosis, emphysema, nose disorders and cancers of
CC the respiratory tissues e.g. lung cancer. The polynucleotide sequences
CC of the invention are useful in gene therapy and antisense therapy.
CC AAS28161-AAS28764 represent genomic sequences encoding for novel
CC human respiratory antigens.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 31994 BP; 7047 A; 7778 C; 7911 G; 9258 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 31994;
Best Local Similarity 100.0%; Pred. No. 1e-13;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2060 GACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCA 2119
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 9222 GACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCA 9281

Qy 2120 C 2120
Db 9282 C 9282

RESULT 66
AAF30035
ID AAF30035 standard; DNA; 81001 BP.
XX
AC AAF30035;
XX
DT 23-APR-2001 (first entry)
XX
DE Human apolipoprotein A-IV-related protein (AA4RP) gene.
XX
KW Apolipoprotein A-IV-related protein; AA4RP; human;
KW biallelic marker; lipid metabolism; liver related disorder;
KW obesity; diabetes; coronary heart disease; diagnosis; gene therapy;
KW chromosome 11; ds.
XX
OS Homo sapiens.
XX

FH	Key	Location/Qualifiers
FT	5'UTR	10946..12946
FT		/*tag= a
FT	CDS	13478..15210
FT		/*tag= b
FT	exon	12947..12958
FT		/*tag= c
FT		/number= 1
FT	intron	12959..13469
FT		/*tag= d
FT		/number= 1
FT	exon	13470..13526
FT		/*tag= e
FT		/number= 2
FT	intron	13527..13640
FT		/*tag= f
FT		/number= 2
FT	exon	13641..13752
FT		/*tag= g
FT		/number= 3
FT	intron	13753..14270
FT		/*tag= h
FT		/number= 3
FT	exon	14271..15968
FT		/*tag= i
FT		/number= 4
FT	3'UTR	15969..17969
FT		/*tag= j
FT	allele	replace(1239,C,T)
FT		/*tag= k
FT		/note= "biallelic marker 20-828-311, polymorphic
FT		base C or T"
FT	allele	replace(12347,C,T)
FT		/*tag= l
FT		/note= "biallelic marker 17-42-319, polymorphic
FT		base C or T"
FT	allele	replace(15241,C,T)
FT		/*tag= m
FT		/note= "biallelic marker 17-41-250, polymorphic
FT		base C or T"
FT	allele	replace(42218,A,G)
FT		/*tag= n
FT		/note= "biallelic marker 20-841-149, polymorphic
FT		base A or G"
FT	allele	replace(45442,A,G)
FT		/*tag= o
FT		/note= "biallelic marker 20-842-115, polymorphic
FT		base A or G"
FT	allele	replace(77058,C,T)
FT		/*tag= p
FT		/note= "biallelic marker 20-853-415, polymorphic
FT		base C or T"

```
FT   primer_bind      929..949
FT                    /*tag= q
FT                    /note= "primer 20-828.pu"
FT   primer_bind      complement (1357..1377)
FT                    /*tag= r
FT                    /note= "primer 20-828.rp"
FT   primer_bind      12029..12050
FT                    /*tag= s
FT                    /note= "primer 17-42.pu"
FT   primer_bind      complement (12581..12603)
FT                    /*tag= t
FT                    /note= "primer 17-42.rp"
FT   primer_bind      14992..15012
FT                    /*tag= u
FT                    /note= "primer 17-41.pu"
FT   primer_bind      complement (15460..15482)
FT                    /*tag= v
FT                    /note= "primer 17-41.rp"
FT   primer_bind      42070..42090
FT                    /*tag= w
FT                    /note= "primer 20-841.pu"
FT   primer_bind      complement (42572..42591)
FT                    /*tag= x
FT                    /note= "primer 20-841.rp"
FT   primer_bind      45328..45347
FT                    /*tag= y
FT                    /note= "primer 20-842.pu"
FT   primer_bind      complement (45863..45883)
FT                    /*tag= z
FT                    /note= "primer 20-842.rp"
FT   primer_bind      76644..76664
FT                    /*tag= aa
FT                    /note= "primer 20-853.pu"
FT   primer_bind      complement (77166..77185)
FT                    /*tag= ab
FT                    /note= "primer 20-842.rp"
FT   primer_bind      1220..1238
FT                    /*tag= ac
FT                    /note= "primer 20-828-311.mis"
FT   primer_bind      complement (1240..1258)
FT                    /*tag= ad
FT                    /note= "primer 20-828-311.mis"
FT   primer_bind      12328..12346
FT                    /*tag= ae
FT                    /note= "primer 17-42-319.mis"
FT   primer_bind      complement (12348..12366)
FT                    /*tag= af
FT                    /note= "primer 17-42-319.mis"
FT   primer_bind      15222...15240
FT                    /*tag= ag
FT                    /note= "primer 17-41-250.mis"
FT   primer_bind      complement (15242..15260)
FT                    /*tag= ah
FT                    /note= "primer 17-41-250.mis"
FT   primer_bind      42199..42237
FT                    /*tag= ai
FT                    /note= "primer 20-841-149.mis"
FT   primer_bind      complement (42219..42237)
FT                    /*tag= aj
FT                    /note= "primer 20-841-149.mis"
FT   primer_bind      45423..45441
FT                    /*tag= ak
FT                    /note= "primer 20-842-115.mis"
FT   primer_bind      complement (45443..45461)
FT                    /*tag= al
FT                    /note= "primer 20-842-115.mis"
FT   primer_bind      77039..77057
FT                    /*tag= am
FT                    /note= "primer 20-853-415.mis"
FT   primer_bind      complement (77059..77077)
FT                    /*tag= an
FT                    /note= "primer 20-853-415.mis"
FT   misc_binding     1227..1251
FT                    /*tag= ao
FT                    /note= "20-828-311 probe"
FT   misc_binding     12335..12359
FT                    /*tag= ap
FT                    /note= "17-42-319 probe"
FT   misc_binding     15229..15253
FT                    /*tag= aq
FT                    /note= "17-41-250 probe"
FT   misc_binding     42206..42230
FT                    /*tag= ar
FT                    /note= "20-841-149 probe"
FT   misc_binding     45430..45454
FT                    /*tag= as
FT                    /note= "20-842-115 probe"
FT   misc_binding     77046..77070
FT                    /*tag= at
FT                    /note= "20-853-415 probe"
XX
PN   WO200100803-A2.
XX
PD   04-JAN-2001.
XX
PF   21-JUN-2000; 2000WO-IB01011.
XX
PR   25-JUN-1999;   99US-0141032.
PR   20-DEC-1999;   99WO-IB02058.
PR   21-DEC-1999;   99US-0469099.
XX
PA   (GEST ) GENSET.
XX
PI   Yen F, Denison B, Bour B, Bihain B, Bougueleret L, Duclert A;
PI   Dumas Milne Edwards J;
XX
DR   WPI; 2001-071485/08.
DR   P-PSDB; AAB20103.
XX
PT   Nucleic acids encoding apolipoprotein A-IV-related proteins (AA4RP) and
PT   biallelic markers of AA4RP, useful for diagnosing lipid metabolism
PT   related disorders and/or liver related disorders -
XX
PS   Claim 1; Page 216-238; 260pp; English.
XX
CC   The present sequence is that of the human apolipoprotein
CC   A-IV-related protein (AA4RP) gene on chromosome 11. The gene
CC   encodes a 366-amino acid protein (see AAB20103). AA4RP is
CC   differentially expressed in obese mouse models, indicating a role
CC   in lipid metabolism related disorders. It appears to be the human
CC   homologue of rat regeneration associated protein (RAP3), which is
CC   believed to be involved in liver regeneration, and is likely to
CC   have a similar function. It also shows 52% similarity to
CC   apolipoprotein A-IV, and is likely to have a similar function. The
CC   invention also provides AA4RP cDNAs (see AAF30036) and polypeptides,
CC   biallelic markers identified in the AA4RP gene and from genomic
CC   regions flanking the gene, and methods for genotyping a nucleic
CC   acid containing 1 or more of the biallelic markers. Also provided
CC   is a method for detecting a statistical correlation between a
CC   biallelic marker allele and a phenotype and/or between a biallelic
CC   marker haplotype and a phenotype. Diagnostic methods are provided
CC   for determining whether an individual is at risk of developing a
CC   lipid metabolism related disorder and/or a liver related disorder,

  Query Match             2.4%;  Score 61;  DB 22;  Length 81001;
  Best Local Similarity   100.0%;  Pred. No. 8.9e-14;
  Matches   61;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   64955 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 65014

Qy    2110 G 2110
           |
Db   65015 G 65015
```

```
RESULT 67
AAD28763/c
ID   AAD28763 standard; DNA; 154465 BP.
XX
AC   AAD28763;
XX
DT   07-MAY-2002  (first entry)
XX
DE   Human AKAP allelic variant (AKAP10-1) gene.
XX
KW   Human; polymorphic A-Kinase anchor protein; AKAP gene; disorder;
KW   neurological; bipolar; cardiovascular; cardiac; proliferative;
KW   neurodegenerative; cardiomyopathy; peripheral retinopathy; obesity;
KW   signal transduction; left ventricular function; Alzheimer's disease;
KW   retinitis pigmentosa; diabetes; single nucleotide polymorphism; SNP;
KW   chromosome 17; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   variation       replace (156277, T,A,G)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism (SNP)"
XX
PN   WO200204489-A2.
XX
PD   17-JAN-2002.
XX
PF   05-JUL-2001; 2001WO-US21308.
XX
PR   10-JUL-2000; 2000US-217251P.
PR   13-OCT-2000; 2000US-240335P.
PR   12-APR-2001; 2001US-0834700.
XX
PA   (SEQU-) SEQUENOM INC.
XX
PI   Braun A;
XX
DR   WPI; 2002-154919/20.
XX
PT   New polynucleotide encoding polymorphic A-Kinase anchor proteins for
PT   detecting an allelic variant of the human gene which is indicative of
PT   an alteration in signal transduction, and is related to a disorder e.g.
PT   Alzheimer's disease  -
XX
PS   Claim 43; Page 246-289; 290pp; English.
XX
CC   The present invention relates to a polynucleotide encoding polymorphic A-
CC   Kinase anchor protein (AKAP), with isoleucine residue at position 646
CC   replaced with valine, leucine or phenylalanine. AKAP is useful for
CC   detecting an allelic variant of a human AKAP10 gene which is indicative
CC   of an alteration in signal transduction, where the alteration is related
CC   to a disorder selected from cardiovascular, cardiac, proliferative,
CC   neurological, neurodegenerative disorders, obesity, diabetes and
CC   peripheral retinopathies, especially the disorders including Alzheimer's
CC   disease, altered left ventricular function, cardiomyopathies, bipolar
CC   disorder and retinitis pigmentosa. The method of the invention is useful
CC   for indicating susceptibility to morbidity and/or increased or early
CC   mortality of a subject, where the predominant allele comprises A at
CC   position corresponding to 2073 of AKAP, or a polymorphic region of AKAP10
CC   comprises a nucleotide other than A at position T corresponding to
CC   position 2073 of AKAP, or other than T of the complement of AKAP, and the
CC   detecting step is performed by allele specific hybridisation, primer
CC   specific extension, oligonucleotide ligation assay, restriction enzyme
CC   site analysis and single-stranded conformation polymorphism analysis, or
CC   the detection is by detecting a signal group from radioisotopes, enzymes,
CC   antigens, antibodies, spectrophotometric reagents, chemiluminescent
CC   reagents, fluorescent reagents and other light producing reagents. AKAP10
CC   gene is located on chromosome 17. The present sequence is human AKAP
CC   allelic variant, AKAP10-1 gene.
XX
SQ   Sequence 154465 BP; 45778 A; 32400 C; 33143 G; 43144 T; 0 other;

  Query Match             2.4%;  Score 61;  DB 24;  Length 154465;
  Best Local Similarity   100.0%;  Pred. No. 8e-14;
  Matches   61;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy   2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  63262 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 63203

Qy   2110 G 2110
           |
Db  63202 G 63202


RESULT 68
AAD28762/c
ID   AAD28762 standard; DNA; 158245 BP.
XX
AC   AAD28762;
XX
DT   07-MAY-2002  (first entry)
XX
DE   Human AKAP allelic variant (AKAP10) gene.
XX
KW   Human; polymorphic A-Kinase anchor protein; AKAP gene; disorder;
KW   neurological; bipolar; cardiovascular; cardiac; proliferative;
KW   neurodegenerative; cardiomyopathy; peripheral retinopathy; obesity;
KW   signal transduction; left ventricular function; Alzheimer's disease;
KW   retinitis pigmentosa; diabetes; single nucleotide polymorphism; SNP;
KW   chromosome 17; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   variation       replace (83587, G)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism (SNP)"
FT   variation       replace (129600, A)
FT                   /*tag=  b
FT                   /standard_name= "Single nucleotide polymorphism (SNP)"
FT   variation       replace (156277, C)
FT                   /*tag=  c
FT                   /standard_name= "Single nucleotide polymorphism (SNP)"
XX
PN   WO200204489-A2.
XX
PD   17-JAN-2002.
XX
PF   05-JUL-2001; 2001WO-US21308.
XX
PR   10-JUL-2000; 2000US-217251P.
PR   13-OCT-2000; 2000US-240335P.
PR   12-APR-2001; 2001US-0834700.
XX
PA   (SEQU-) SEQUENOM INC.
XX
PI   Braun A;
XX
DR   WPI; 2002-154919/20.
XX
PT   New polynucleotide encoding polymorphic A-Kinase anchor proteins for
PT   detecting an allelic variant of the human gene which is indicative of
PT   an alteration in signal transduction, and is related to a disorder e.g.
PT   Alzheimer's disease  -
XX
PS   Claim 47; Page 203-246; 290pp; English.
XX
CC   The present invention relates to a polynucleotide encoding polymorphic A-
CC   Kinase anchor protein (AKAP), with isoleucine residue at position 646
CC   replaced with valine, leucine or phenylalanine. AKAP is useful for
CC   detecting an allelic variant of a human AKAP10 gene which is indicative
CC   of an alteration in signal transduction, where the alteration is related
CC   to a disorder selected from cardiovascular, cardiac, proliferative,
```

CC neurological, neurodegenerative disorders, obesity, diabetes and
CC peripheral retinopathies, especially the disorders including Alzheimer's
CC disease, altered left ventricular function, cardiomyopathies, bipolar
CC disorder and retinitis pigmentosa. The method of the invention is useful
CC for indicating susceptibility to morbidity and/or increased or early
CC mortality of a subject, where the predominant allele comprises A at
CC position corresponding to 2073 of AKAP, or a polymorphic region of AKAP10
CC comprises a nucleotide other than A at position T corresponding to
CC position 2073 of AKAP, or other than T of the complement of AKAP, and the
CC detecting step is performed by allele specific hybridisation, primer
CC specific extension, oligonucleotide ligation assay, restriction enzyme
CC site analysis and single-stranded conformation polymorphism analysis, or
CC the detection is by detecting a signal group from radioisotopes, enzymes,
CC antigens, antibodies, spectrophotometric reagents, chemiluminescent
CC reagents, fluorescent reagents and other light producing reagents. The
CC present sequence is human AKAP10 gene which is located on chromosome 17.
XX
SQ Sequence 158245 BP; 47003 A; 32825 C; 33938 G; 44479 T; 0 other;

Query Match 2.4%; Score 61; DB 24; Length 158245;
Best Local Similarity 100.0%; Pred. No. 8e-14;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 63262 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 63203

Qy 2110 G 2110
|
Db 63202 G 63202

RESULT 69
AAH02340/c
ID AAH02340 standard; DNA; 161425 BP.
XX
AC AAH02340;
XX
DT 12-JUN-2001 (first entry)
XX
DE Human AKAP10 gene SEQ ID NO: 36.
XX
KW Database; polymorphism; SNP; human; genetic marker; disease; infection;
KW drug response; ds.
XX
OS Homo sapiens.
XX
PN WO200127857-A2.
XX
PD 19-APR-2001.
XX
PF 13-OCT-2000; 2000WO-US28413.
XX
PR 13-OCT-1999; 99US-0159176.
PR 10-JUL-2000; 2000US-0217251.
PR 10-JUL-2000; 2000US-0217658.
PR 19-SEP-2000; 2000US-0663968.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Braun A, Koester H, Van Den Boom D, Ping Y, Rodi C, He L, Chiu N;
PI Jurinke C;
XX
DR WPI; 2001-273865/28.
XX
PT Producing a database for identifying polymorphic genetic markers,
PT comprises obtaining data relating to members of a healthy population
PT and entering the information into a database -
XX
PS Example 3; Page 241-288; 304pp; English.
XX
CC The present invention provides a database of human samples obtained from
CC healthy individuals which can be used to identify polymorphic genetic
CC markers. Data obtained for the database can be used to sort the samples
CC by parameters such as age, sex and ethnicity. This is useful in linking
CC markers with diseases, susceptibility to infection and drug responses.
CC The present sequence was used in an assay to demonstrate the uses of the
CC database of the invention.
XX
SQ Sequence 161425 BP; 47858 A; 33576 C; 34682 G; 45309 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 161425;
Best Local Similarity 100.0%; Pred. No. 7.9e-14;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 63262 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 63203

Qy 2110 G 2110
|
Db 63202 G 63202

RESULT 70
AAH02339/c
ID AAH02339 standard; DNA; 162025 BP.
XX
AC AAH02339;
XX
DT 12-JUN-2001 (first entry)
XX
DE Human AKAP10 gene SEQ ID NO: 35.
XX
KW Database; polymorphism; SNP; human; genetic marker; disease; infection;
KW drug response; ds.
XX
OS Homo sapiens.
XX
PN WO200127857-A2.
XX
PD 19-APR-2001.
XX
PF 13-OCT-2000; 2000WO-US28413.
XX
PR 13-OCT-1999; 99US-0159176.
PR 10-JUL-2000; 2000US-0217251.
PR 10-JUL-2000; 2000US-0217658.
PR 19-SEP-2000; 2000US-0663968.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Braun A, Koester H, Van Den Boom D, Ping Y, Rodi C, He L, Chiu N;
PI Jurinke C;
XX
DR WPI; 2001-273865/28.
XX
PT Producing a database for identifying polymorphic genetic markers,
PT comprises obtaining data relating to members of a healthy population
PT and entering the information into a database -
XX
PS Example 3; Page 196-241; 304pp; English.
XX
CC The present invention provides a database of human samples obtained from
CC healthy individuals which can be used to identify polymorphic genetic
CC markers. Data obtained for the database can be used to sort the samples
CC by parameters such as age, sex and ethnicity. This is useful in linking
CC markers with diseases, susceptibility to infection and drug responses.
CC The present sequence was used in an assay to demonstrate the uses of the
CC database of the invention.
XX
SQ Sequence 162025 BP; 48006 A; 33691 C; 34805 G; 45523 T; 0 other;

Query Match 2.4%; Score 61; DB 22; Length 162025;
Best Local Similarity 100.0%; Pred. No. 7.9e-14;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy   2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  63262 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 63203

Qy   2110 G 2110
          |
Db  63202 G 63202
```

RESULT 71
AAD28758/c
ID AAD28758 standard; DNA; 162025 BP.
XX
AC AAD28758;
XX
DT 07-MAY-2002 (first entry)
XX
DE Human AKAP allelic variant (AKAP10-6) gene.
XX
KW Human; polymorphic A-Kinase anchor protein; AKAP gene; disorder;
KW neurological; bipolar; cardiovascular; cardiac; proliferative;
KW neurodegenerative; cardiomyopathy; peripheral retinopathy; obesity;
KW signal transduction; left ventricular function; Alzheimer's disease;
KW retinitis pigmentosa; diabetes; single nucleotide polymorphism; SNP;
KW chromosome 17; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT variation replace (83587, C,A,T)
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism (SNP)"
XX
PN WO200204489-A2.
XX
PD 17-JAN-2002.
XX
PF 05-JUL-2001; 2001WO-US21308.
XX
PR 10-JUL-2000; 2000US-217251P.
PR 13-OCT-2000; 2000US-240335P.
PR 12-APR-2001; 2001US-0834700.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Braun A;
XX
DR WPI; 2002-154919/20.
XX
PT New polynucleotide encoding polymorphic A-Kinase anchor proteins for
PT detecting an allelic variant of the human gene which is indicative of
PT an alteration in signal transduction, and is related to a disorder e.g.
PT Alzheimer's disease -
XX
PS Claim 43; Page 116-159; 290pp; English.
XX
CC The present invention relates to a polynucleotide encoding polymorphic A-
CC Kinase anchor protein (AKAP), with isoleucine residue at position 646
CC replaced with valine, leucine or phenylalanine. AKAP is useful for
CC detecting an allelic variant of a human AKAP10 gene which is indicative
CC of an alteration in signal transduction, where the alteration is related
CC to a disorder selected from cardiovascular, cardiac, proliferative,
CC neurological, neurodegenerative disorders, obesity, diabetes and
CC peripheral retinopathies, especially the disorders including Alzheimer's
CC disease, altered left ventricular function, cardiomyopathies, bipolar
CC disorder and retinitis pigmentosa. The method of the invention is useful
CC for indicating susceptibility to morbidity and/or increased or early
CC mortality of a subject, where the predominant allele comprises A at
CC position corresponding to 2073 of AKAP, or a polymorphic region of AKAP10
CC comprises a nucleotide other than A at position T corresponding to
CC position 2073 of AKAP, or other than T of the complement of AKAP, and the
CC detecting step is performed by allele specific hybridisation, primer
CC specific extension, oligonucleotide ligation assay, restriction enzyme
CC site analysis and single-stranded conformation polymorphism analysis, or
CC the detection is by detecting a signal group from radioisotopes, enzymes,
CC antigens, antibodies, spectrophotometric reagents, chemiluminescent
CC reagents, fluorescent reagents and other light producing reagents. AKAP10
CC gene is located on chromosome 17. The present sequence is human AKAP
CC allelic variant, AKAP10-6 gene.
XX
SQ Sequence 162025 BP; 48005 A; 33690 C; 34807 G; 45523 T; 0 other;

```
  Query Match             2.4%;  Score 61;  DB 24;  Length 162025;
  Best Local Similarity   100.0%;  Pred. No. 7.9e-14;
  Matches   61;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy   2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  63262 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 63203

Qy   2110 G 2110
          |
Db  63202 G 63202
```

RESULT 72
AAD28759/c
ID AAD28759 standard; DNA; 162025 BP.
XX
AC AAD28759;
XX
DT 07-MAY-2002 (first entry)
XX
DE Human AKAP allelic variant (AKAP10-7) gene.
XX
KW Human; polymorphic A-Kinase anchor protein; AKAP gene; disorder;
KW neurological; bipolar; cardiovascular; cardiac; proliferative;
KW neurodegenerative; cardiomyopathy; peripheral retinopathy; obesity;
KW signal transduction; left ventricular function; Alzheimer's disease;
KW retinitis pigmentosa; diabetes; single nucleotide polymorphism; SNP;
KW chromosome 17; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT variation replace (129600, G,C,T)
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism (SNP)"
XX
PN WO200204489-A2.
XX
PD 17-JAN-2002.
XX
PF 05-JUL-2001; 2001WO-US21308.
XX
PR 10-JUL-2000; 2000US-217251P.
PR 13-OCT-2000; 2000US-240335P.
PR 12-APR-2001; 2001US-0834700.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Braun A;
XX
DR WPI; 2002-154919/20.
XX
PT New polynucleotide encoding polymorphic A-Kinase anchor proteins for
PT detecting an allelic variant of the human gene which is indicative of
PT an alteration in signal transduction, and is related to a disorder e.g.
PT Alzheimer's disease -
XX
PS Claim 43; Page 159-202; 290pp; English.
XX
CC The present invention relates to a polynucleotide encoding polymorphic A-
CC Kinase anchor protein (AKAP), with isoleucine residue at position 646
CC replaced with valine, leucine or phenylalanine. AKAP is useful for

```
CC   detecting an allelic variant of a human AKAP10 gene which is indicative
CC   of an alteration in signal transduction, where the alteration is related
CC   to a disorder selected from cardiovascular, cardiac, proliferative,
CC   neurological, neurodegenerative disorders, obesity, diabetes and
CC   peripheral retinopathies, especially the disorders including Alzheimer's
CC   disease, altered left ventricular function, cardiomyopathies, bipolar
CC   disorder and retinitis pigmentosa. The method of the invention is useful
CC   for indicating susceptibility to morbidity and/or increased or early
CC   mortality of a subject, where the predominant allele comprises A at
CC   position corresponding to 2073 of AKAP, or a polymorphic region of AKAP10
CC   comprises a nucleotide other than A at position T corresponding to
CC   position 2073 of AKAP, or other than T of the complement of AKAP, and the
CC   detecting step is performed by allele specific hybridisation, primer
CC   specific extension, oligonucleotide ligation assay, restriction enzyme
CC   site analysis and single-stranded conformation polymorphism analysis, or
CC   the detection is by detecting a signal group from radioisotopes, enzymes,
CC   antigens, antibodies, spectrophotometric reagents, chemiluminescent
CC   reagents, fluorescent reagents and other light producing reagents. AKAP10
CC   gene is located on chromosome 17. The present sequence is human AKAP
CC   allelic variant, AKAP10-7 gene.
XX
SQ   Sequence 162025 BP; 48007 A; 33691 C; 34804 G; 45523 T; 0 other;

  Query Match             2.4%;  Score 61;  DB 24;  Length 162025;
  Best Local Similarity   100.0%;  Pred. No. 7.9e-14;
  Matches   61;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    2050 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 2109
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   63262 TCGAACTCCTGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAG 63203

Qy    2110 G 2110
           |
Db   63202 G 63202


RESULT 73
ABN35717
ID   ABN35717 standard; DNA; 60 BP.
XX
AC   ABN35717;
XX
DT   15-JUL-2002  (first entry)
XX
DE   Human spliced transcript detection oligonucleotide SEQ ID NO:8465.
XX
KW   Human; mouse; rat; splice transcript; detection; RNA transcript;
KW   splice variant; transcriptome; oligonucleotide library; ss.
XX
OS   Homo sapiens.
XX
PN   WO200210449-A2.
XX
PD   07-FEB-2002.
XX
PF   20-JUL-2001; 2001WO-IB01903.
XX
PR   28-JUL-2000; 2000US-221607P.
PR   02-MAY-2001; 2001US-287724P.
XX
PA   (COMP-) COMPUGEN INC.
XX
PI   Shoshan A,  Wasserman A,  Mintz E,  Mintz L,  Faigler S;
XX
DR   WPI; 2002-257383/30.
XX
PT   New oligonucleotide libraries comprising oligonucleotides which
PT   selectively hybridize to mRNAs transcribed from a transcription unit of
PT   a genome, useful for detecting tissue-, pathology-, and
PT   developmental-specific genes -
XX
PS   Example 1; SEQ ID 8465; 47pp; English.
XX
CC   The present invention describes oligonucleotide libraries for detecting
CC   messenger RNAs that populate a (sub-)transcriptome, where the
CC   (sub-)transcriptome comprises messenger RNAs transcribed from multiple
CC   transcription units that populate a genome. The library comprises
CC   several oligonucleotides, each capable of hybridising selectively to a
CC   set of messenger RNAs transcribed from a given transcription unit of
CC   the genome, which encodes one or more messenger RNA splice variants.
CC   The oligonucleotide libraries are useful for detecting mRNAs from a
CC   biological sample, in expression profiling studies, in qualitatively or
CC   quantitatively characterising the corresponding transcriptome, and in
CC   detecting RNA transcripts and splice variants of human or animal
CC   transcriptomes. The libraries may also be used as specialised mini
CC   libraries to detect transcripts of a sub-transcriptome under a
CC   particular biological or pathological state, and so allowing the
CC   detection of tissue- and pathology-specific genes such as those genes
CC   only expressed in specific tissue under a specific pathological
CC   condition; to detect developmental specific genes; and to detect RNA
CC   transcripts and splice variants of a transcriptome of a patient suffering
CC   from a particular disorder. ABN27253 to ABN59589 represent
CC   oligonucleotide sequences from rats, humans and mice, which are used in
CC   the exemplification of the present invention.
CC   N.B. The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 60 BP; 16 A; 12 C; 16 G; 16 T; 0 other;

  Query Match             2.3%;  Score 60;  DB 24;  Length 60;
  Best Local Similarity   100.0%;  Pred. No. 6.9e-13;
  Matches   60;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    2459 TCCCAAGCTACAGGTGGGGTGGGAAAGGCTTTATCAGGTATCATCAACAGGTTCTCAATT 2518
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 TCCCAAGCTACAGGTGGGGTGGGAAAGGCTTTATCAGGTATCATCAACAGGTTCTCAATT 60


RESULT 74
AAQ13332
ID   AAQ13332 standard; DNA; 8174 BP.
XX
AC   AAQ13332;
XX
DT   07-NOV-1991  (first entry)
XX
DE   GDP-Fuc:beta-D-galactoside alpha(1,2)-fucosyltransferase gene.
XX
KW   Glycosyltransferase.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             4686..5783
FT                   /*tag=  a
XX
PN   WO9112340-A.
XX
PD   22-AUG-1991.
XX
PF   14-FEB-1991;   91WO-US00899.
XX
PR   12-DEC-1990;   90US-0627621.
PR   14-FEB-1990;   90US-0479858.
PR   14-FEB-1990;   90US-0480133.
XX
PA   (UNMI ) UNIV OF MICHIGAN.
XX
PI   Lowe JB;
XX
DR   WPI; 1991-267151/36.
DR   P-PSDB; AAR13751.
XX
PT   Isolation of gene conveying post-translational characteristic -
PT   e.g. the presence of soluble or membrane bound oligo or
```

PT polysaccharide or glycosyltransferase.
XX
PS Disclosure; Fig 3; 155pp; English.
XX
CC The DNA encodes a protein sequence capable of functioning as a
CC GDP- Fuc:[beta-D-Gal alpha(1,2)- fucosyltransferase. The sequence
CC coded by nucleotides 4782 - 5780 represents the functional protein.
CC The enzyme produced by the DNA sequence can be used in enzymatic
CC fucosylation of chain-terminating galactose residues on lactose-
CC amine or neolacto type beta-D-galactoside to alpha-2-L-fucose
CC residues. See also AAQ13330-Q13333.
XX
SQ Sequence 8174 BP; 1628 A; 2229 C; 2322 G; 1995 T; 0 other;

Query Match 2.3%; Score 60; DB 12; Length 8174;
Best Local Similarity 100.0%; Pred. No. 3.1e-13;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2061 ACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCAC 2120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4227 ACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCAC 4286

RESULT 75
AAQ56908
ID AAQ56908 standard; DNA; 8174 BP.
XX
AC AAQ56908;
XX
DT 26-JUL-1994 (first entry)
XX
DE DNA encoding a glycosyltransferase.
XX
KW Glycosyltransferase; fucosyltransferase; GDP-Fuc; in vitro; cell;
KW surface; oligosaccharide; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 4686..5783
FT /*tag= a
XX
PN WO9402616-A.
XX
PD 03-FEB-1994.
XX
PF 20-JUL-1993; 93WO-US06703.
XX
PR 20-JUL-1992; 92US-0914281.
XX
PA (UNMI) UNIV MICHIGAN.
XX
PI Lowe JB;
XX
DR WPI; 1994-048874/06.
DR P-PSDB; AAR45936.
XX
PT DNA fragment encoding a glycosyltransferase - can be used for in
PT vitro reactions to modify cell surface oligosaccharide(s) e.g.
PT blood gp. determinants, to protect against transplant rejection
XX
PS Disclosure; Fig 3; 249pp; English.
XX
CC The sequence is that encoding human glycosyl transferase. The enzyme
CC produced by the DNA may be non glycosylated. This prevents premature
CC loss of enzyme activity. It can also be used in in vitro reactions to
CC modify cell surface oligosaccharide mols. e.g. blood group determinants.
CC See also AAQ56905-12.
XX
SQ Sequence 8174 BP; 1628 A; 2228 C; 2322 G; 1996 T; 0 other;

Query Match 2.3%; Score 60; DB 15; Length 8174;
Best Local Similarity 100.0%; Pred. No. 3.1e-13;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2061 ACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCAC 2120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4227 ACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCAC 4286

Search completed: March 30, 2003, 17:01:50
Job time : 2486 secs